text_a,span_text_a,text_b,span_text_b,normalized_vertical_gap,indentation_change,same_alignment,is_centered_A,is_centered_B,font_size_a,font_size_b,font_size_diff,same_font,is_bold_A,is_bold_B,is_italic_A,is_italic_B,is_monospace_A,is_monospace_B,same_bold,same_italic,same_monospace,line_a_ends_punctuation,line_b_starts_lowercase,is_linea_in_rectangle,is_lineb_in_rectangle,both_in_table,neither_in_table,is_linea_hashed,is_lineb_hashed,both_hashed,neither_hashed,page_number_a,page_number_b,label
et al. 24 proposed a fusion model that combined complementary molecular representations. Their method,et al. [24] proposed a fusion model that combined complementary molecular representations. Their method,"utilized a 3D CNN to capture local spatial features and a spatial GNN to encode global structural information,","utilized a 3D CNN to capture local spatial features and a spatial GNN to encode global structural information,",1,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"utilized a 3D CNN to capture local spatial features and a spatial GNN to encode global structural information,","utilized a 3D CNN to capture local spatial features and a spatial GNN to encode global structural information,",integrating both in a fused architecture.,integrating both in a fused architecture.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
integrating both in a fused architecture.,integrating both in a fused architecture.,"The IGN framework 80 modeled protein-ligand complexes using three distinct molecular graphs, each","The IGN framework [80] modeled protein-ligand complexes using three distinct molecular graphs, each",1,14.94,0,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0
"The IGN framework 80 modeled protein-ligand complexes using three distinct molecular graphs, each","The IGN framework [80] modeled protein-ligand complexes using three distinct molecular graphs, each","incorporating both 3D structural and chemical properties. MP-GNN 81 introduced a multiphysical molecular graph representation, which systematically captured a wide range of molecular interactions across different atom types and physical scales. However, most existing biomolecular GNNs rely on covalent-bondbased graph constructions, which often fail to effectively characterize non-covalent interactions essential for","based graph constructions, which often fail to effectively characterize non-covalent interactions essential for",12.77,-14.94,0,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"incorporating both 3D structural and chemical properties. MP-GNN 81 introduced a multiphysical molecular graph representation, which systematically captured a wide range of molecular interactions across different atom types and physical scales. However, most existing biomolecular GNNs rely on covalent-bondbased graph constructions, which often fail to effectively characterize non-covalent interactions essential for","based graph constructions, which often fail to effectively characterize non-covalent interactions essential for",modeling biomolecular complexes.,modeling biomolecular complexes.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
modeling biomolecular complexes.,modeling biomolecular complexes.,GraphscoreDTA 82 advanced this field by integrating a bitransport information mechanism and Vina,GraphscoreDTA [82] advanced this field by integrating a bitransport information mechanism and Vina,1,14.94,0,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0
GraphscoreDTA 82 advanced this field by integrating a bitransport information mechanism and Vina,GraphscoreDTA [82] advanced this field by integrating a bitransport information mechanism and Vina,distance optimization terms to better capture the mutual information between proteins and ligands. This,distance optimization terms to better capture the mutual information between proteins and ligands. This,1,-14.94,0,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
distance optimization terms to better capture the mutual information between proteins and ligands. This,distance optimization terms to better capture the mutual information between proteins and ligands. This,"method also highlighted critical atomic and residue-level features. In contrast to the above, NERE 25","method also highlighted critical atomic and residue-level features. In contrast to the above, NERE [25]",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"method also highlighted critical atomic and residue-level features. In contrast to the above, NERE 25","method also highlighted critical atomic and residue-level features. In contrast to the above, NERE [25]","proposed an unsupervised approach to binding energy prediction, framing it as a generative modeling task.","proposed an unsupervised approach to binding energy prediction, framing it as a generative modeling task.",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"proposed an unsupervised approach to binding energy prediction, framing it as a generative modeling task.","proposed an unsupervised approach to binding energy prediction, framing it as a generative modeling task.","Their method, based on Neural Euler’s Rotation Equations NERE, predicted molecular rotations by modeling the forces and torques between ligand and protein atoms. However, the current implementation of","eling the forces and torques between ligand and protein atoms. However, the current implementation of",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,1
"Their method, based on Neural Euler’s Rotation Equations NERE, predicted molecular rotations by modeling the forces and torques between ligand and protein atoms. However, the current implementation of","eling the forces and torques between ligand and protein atoms. However, the current implementation of","NERE for antibody modeling only considers backbone atoms and omits side-chain atoms, which are crucial","NERE for antibody modeling only considers backbone atoms and omits side-chain atoms, which are crucial",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1
"NERE for antibody modeling only considers backbone atoms and omits side-chain atoms, which are crucial","NERE for antibody modeling only considers backbone atoms and omits side-chain atoms, which are crucial",for accurately estimating binding affinity.,for accurately estimating binding affinity.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
for accurately estimating binding affinity.,for accurately estimating binding affinity.,"Docking, a central process in drug discovery, has also seen innovation through GNN-based approaches.","Docking, a central process in drug discovery, has also seen innovation through GNN-based approaches.",1,14.94,0,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0
"Docking, a central process in drug discovery, has also seen innovation through GNN-based approaches.","Docking, a central process in drug discovery, has also seen innovation through GNN-based approaches.","E3Bind 26 introduced an end-to-end model that directly generates ligand coordinates, thus eliminating","E3Bind [26] introduced an end-to-end model that directly generates ligand coordinates, thus eliminating",1,-14.94,0,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,1
"E3Bind 26 introduced an end-to-end model that directly generates ligand coordinates, thus eliminating","E3Bind [26] introduced an end-to-end model that directly generates ligand coordinates, thus eliminating","the need for traditional sampling procedures and coordinate reconstructions. Similarly, FABind 83 combined pocket prediction and docking in an integrated model for fast and accurate binding pose prediction. A",bined pocket prediction and docking in an integrated model for fast and accurate binding pose prediction. A,4.92,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"the need for traditional sampling procedures and coordinate reconstructions. Similarly, FABind 83 combined pocket prediction and docking in an integrated model for fast and accurate binding pose prediction. A",bined pocket prediction and docking in an integrated model for fast and accurate binding pose prediction. A,"unique ligand-informed pocket prediction module was used to guide the docking process, with successive","unique ligand-informed pocket prediction module was used to guide the docking process, with successive",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"unique ligand-informed pocket prediction module was used to guide the docking process, with successive","unique ligand-informed pocket prediction module was used to guide the docking process, with successive",refinements optimizing the ligand-protein binding pose. The model further enhanced the docking process by,refinements optimizing the ligand-protein binding pose. The model further enhanced the docking process by,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
refinements optimizing the ligand-protein binding pose. The model further enhanced the docking process by,refinements optimizing the ligand-protein binding pose. The model further enhanced the docking process by,"incrementally integrating the predicted pockets to optimize protein-ligand binding. However, ablation studies indicated that different components contribute to the model’s performance in varying degrees, suggesting","ies indicated that different components contribute to the model’s performance in varying degrees, suggesting",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"incrementally integrating the predicted pockets to optimize protein-ligand binding. However, ablation studies indicated that different components contribute to the model’s performance in varying degrees, suggesting","ies indicated that different components contribute to the model’s performance in varying degrees, suggesting","potential inefficiencies in the overall architecture. More recently, NeuralMD 84 provided a fine-grained","potential inefficiencies in the overall architecture. More recently, NeuralMD [84] provided a fine-grained",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"potential inefficiencies in the overall architecture. More recently, NeuralMD 84 provided a fine-grained","potential inefficiencies in the overall architecture. More recently, NeuralMD [84] provided a fine-grained","simulation of protein-ligand binding dynamics. The model included BindingNet, which adhered to group","simulation of protein-ligand binding dynamics. The model included BindingNet, which adhered to group",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"simulation of protein-ligand binding dynamics. The model included BindingNet, which adhered to group","simulation of protein-ligand binding dynamics. The model included BindingNet, which adhered to group","symmetry and captured multi-level interactions, and a neural ordinary differential equation ODE solver","symmetry and captured multi-level interactions, and a neural ordinary differential equation (ODE) solver",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"symmetry and captured multi-level interactions, and a neural ordinary differential equation ODE solver","symmetry and captured multi-level interactions, and a neural ordinary differential equation (ODE) solver",that modeled the physical trajectories of atoms based on Newtonian mechanics.,that modeled the physical trajectories of atoms based on Newtonian mechanics.,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
that modeled the physical trajectories of atoms based on Newtonian mechanics.,that modeled the physical trajectories of atoms based on Newtonian mechanics.,"EquiPocket 85, distinct from the aforementioned methods, focused specifically on predicting ligand","EquiPocket [85], distinct from the aforementioned methods, focused specifically on predicting ligand",1,14.94,0,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0
"EquiPocket 85, distinct from the aforementioned methods, focused specifically on predicting ligand","EquiPocket [85], distinct from the aforementioned methods, focused specifically on predicting ligand",binding sites for given 3D protein structures. It introduced three novel modules: a local geometric modeling,binding sites for given 3D protein structures. It introduced three novel modules: a local geometric modeling,1,-14.94,0,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
binding sites for given 3D protein structures. It introduced three novel modules: a local geometric modeling,binding sites for given 3D protein structures. It introduced three novel modules: a local geometric modeling,"module to extract features from individual surface atoms, a global structural module to encode the chemical and spatial context of the entire protein, and a surface message-passing module to learn surface-level","ical and spatial context of the entire protein, and a surface message-passing module to learn surface-level",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"module to extract features from individual surface atoms, a global structural module to encode the chemical and spatial context of the entire protein, and a surface message-passing module to learn surface-level","ical and spatial context of the entire protein, and a surface message-passing module to learn surface-level","geometric patterns. In contrast to CNN-based methods, which suffer from inefficiencies due to voxelization","geometric patterns. In contrast to CNN-based methods, which suffer from inefficiencies due to voxelization",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"geometric patterns. In contrast to CNN-based methods, which suffer from inefficiencies due to voxelization","geometric patterns. In contrast to CNN-based methods, which suffer from inefficiencies due to voxelization","of irregular protein surfaces, EquiPocket avoids computational redundancy and excessive memory usage","of irregular protein surfaces, EquiPocket avoids computational redundancy and excessive memory usage",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"of irregular protein surfaces, EquiPocket avoids computational redundancy and excessive memory usage","of irregular protein surfaces, EquiPocket avoids computational redundancy and excessive memory usage",through its surface-based geometric design.,through its surface-based geometric design.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
through its surface-based geometric design.,through its surface-based geometric design.,5 Prediction of Drug-Drug Interactions,Prediction of Drug-Drug Interactions,7.08,21.52,0,0,0,9.96,14.35,4.38,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0
5 Prediction of Drug-Drug Interactions,Prediction of Drug-Drug Interactions,"Predicting and understanding DDIs is a critical step in computational drug discovery, especially in the context of drug combination therapies 86, 87, 88, in which case multiple drugs are commonly used together","text of drug combination therapies [86, 87, 88], in which case multiple drugs are commonly used together",8.03,-21.52,0,0,0,14.35,9.96,-4.38,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0
"Predicting and understanding DDIs is a critical step in computational drug discovery, especially in the context of drug combination therapies 86, 87, 88, in which case multiple drugs are commonly used together","text of drug combination therapies [86, 87, 88], in which case multiple drugs are commonly used together","in clinical practice to treat complex diseases such as cancer 89, 90, 91. However, polypharmacy elevates","in clinical practice to treat complex diseases such as cancer [89, 90, 91]. However, polypharmacy elevates",1,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"in clinical practice to treat complex diseases such as cancer 89, 90, 91. However, polypharmacy elevates","in clinical practice to treat complex diseases such as cancer [89, 90, 91]. However, polypharmacy elevates","the risk of adverse DDIs, potentially compromising therapeutic efficacy, posing serious health risks, and","the risk of adverse DDIs, potentially compromising therapeutic efficacy, posing serious health risks, and",1,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"the risk of adverse DDIs, potentially compromising therapeutic efficacy, posing serious health risks, and","the risk of adverse DDIs, potentially compromising therapeutic efficacy, posing serious health risks, and","increasing healthcare costs 92, 93, 94. Historically, many DDIs were discovered via clinical case reports","increasing healthcare costs [92, 93, 94]. Historically, many DDIs were discovered via clinical case reports",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"increasing healthcare costs 92, 93, 94. Historically, many DDIs were discovered via clinical case reports","increasing healthcare costs [92, 93, 94]. Historically, many DDIs were discovered via clinical case reports","or mined from electronic health records EHRs 95, 96. Computational approaches, particularly those","or mined from electronic health records (EHRs) [95, 96]. Computational approaches, particularly those",1,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
DDI Event,DDI Event,Graph,Graph,0.38,4.35,1,0,0,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Graph,Graph,Red Edge:,Red Edge:,1.23,17.93,0,0,0,4.9,3.5,-1.4,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,2,2,1
Red Edge:,Red Edge:,DDI type 1,DDI type 1,0.27,0,1,0,0,3.5,3.5,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,2,2,1
DDI type 1,DDI type 1,Blue Edge:,Blue Edge:,0.93,-0.29,1,0,0,3.5,3.5,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,2,2,1
Blue Edge:,Blue Edge:,DDI type 2,DDI type 2,0.27,0.29,1,0,0,3.5,3.5,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,2,2,1
DDI type 2,DDI type 2,Green Edge:,Green Edge:,0.92,-1.66,1,0,0,3.5,3.5,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,2,2,1
Green Edge:,Green Edge:,DDI type 3,DDI type 3,0.27,1.66,1,0,0,3.5,3.5,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,2,2,1
DDI type 3,DDI type 3,Drug,Drug,15.99,-16.43,0,0,0,3.5,4.9,1.4,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,2,2,1
Drug,Drug,Structural,Structural,0.38,-5.85,0,0,0,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Structural,Structural,Information,Information,-9.14,158.01,0,0,1,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Information,Information,Patient Medical,Patient Medical,27.06,-164.27,0,1,0,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Patient Medical,Patient Medical,History,History,0.38,9.39,0,0,0,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
History,History,General DDI Prediction,General DDI Prediction,-57.71,95.4,0,0,1,4.9,8.75,3.85,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
General DDI Prediction,General DDI Prediction,Embeddings,Embeddings,2.32,56.67,0,1,1,8.75,4.9,-3.85,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Embeddings,Embeddings,GNN Blocks,GNN Blocks,5.2,-65.49,0,1,1,4.9,3.85,-1.05,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
GNN Blocks,GNN Blocks,Auxiliary,Auxiliary,12.1,71.42,0,1,1,3.85,4.9,1.05,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Auxiliary,Auxiliary,Information,Information,9.86,-163.04,0,1,0,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Information,Information,GNN Blocks Embeddings,GNN Blocks,-2.79,93.01,0,0,1,4.9,3.85,-1.05,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
GNN Blocks Embeddings,GNN Blocks,Embeddings,Embeddings,-0.65,66.08,0,1,1,3.85,4.9,1.05,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Embeddings,Embeddings,Embedding Block,Embedding Block,25.22,-77.11,0,1,1,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Embedding Block,Embedding Block,Aggregation,Aggregation,-37.21,121.25,0,1,0,4.9,3.85,-1.05,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Aggregation,Aggregation,Aggregation,Aggregation,32.93,0,1,0,0,3.85,3.85,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Aggregation,Aggregation,MLP,MLP,-35.06,68.43,0,0,0,3.85,3.85,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
MLP,MLP,MLP,MLP,32.93,-2.39,1,0,0,3.85,3.85,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
MLP,MLP,Latent,Latent,-42.62,-25.55,0,0,0,3.85,4.9,1.05,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Latent,Latent,Embedding,Embeddings,35.58,-85.28,0,0,1,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Embedding,Embeddings,Latent,Latent,-4.12,85.28,0,1,0,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Latent,Latent,Embedding,Embedding,-33.8,-5.98,0,0,0,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Embedding,Embedding,DDI,DDI,-3.26,62.22,0,0,0,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
DDI,DDI,Prediction,Prediction,0.38,-7.76,0,0,0,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Prediction,Prediction,Drug Safe,Drug Safe,31.01,0.41,1,0,0,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Drug Safe,Drug Safe,Usage Score,Usage Score,0.38,-3.27,1,0,0,4.9,4.9,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Usage Score,Usage Score,0.9,0.9,1.24,13.07,0,0,0,4.9,2.1,-2.8,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
0.9,0.9,0.2,0.2,1.18,0.22,1,0,0,2.1,2.1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
0.2,0.2,0.1,0.1,1.18,0,1,0,0,2.1,2.1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
0.1,0.1,0.3,0.3,1.18,0,1,0,0,2.1,2.1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
0.3,0.3,0.8,0.8,1.18,0,1,0,0,2.1,2.1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
0.8,0.8,0.2,0.2,1.3,0,1,0,0,2.1,2.1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
0.2,0.2,0.75,0.75,1.07,-0.58,1,0,0,2.1,2.1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
0.75,0.75,Drug Recommendation for Individual Patients,Drug Recommendation for Individual Patients,10.5,-240.17,0,0,1,2.1,8.75,6.65,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,2,2,1
Drug Recommendation for Individual Patients,Drug Recommendation for Individual Patients,Figure 4: The general process of DDI prediction based on GNN models. Possible inputs for the general DDI,Figure 4: The general process of DDI prediction based on GNN models. Possible inputs for the general DDI,7.58,-128.12,0,1,1,8.75,9.96,1.21,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,2,2,0
Figure 4: The general process of DDI prediction based on GNN models. Possible inputs for the general DDI,Figure 4: The general process of DDI prediction based on GNN models. Possible inputs for the general DDI,"prediction the one inside the small rectangle include DDI event graphs, and drug molecular structures,","prediction (the one inside the small rectangle) include DDI event graphs, and drug molecular structures,",0.9,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,2,2,1
"prediction the one inside the small rectangle include DDI event graphs, and drug molecular structures,","prediction (the one inside the small rectangle) include DDI event graphs, and drug molecular structures,",either individually or jointly. Additional auxiliary data can be incorporated into the models. GNN blocks,either individually or jointly. Additional auxiliary data can be incorporated into the models. GNN blocks,0.9,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,2,2,1
either individually or jointly. Additional auxiliary data can be incorporated into the models. GNN blocks,either individually or jointly. Additional auxiliary data can be incorporated into the models. GNN blocks,"map the inputs into the latent space, which will be utilized for DDI prediction. By including patient medical","map the inputs into the latent space, which will be utilized for DDI prediction. By including patient medical",0.9,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,2,2,1
"map the inputs into the latent space, which will be utilized for DDI prediction. By including patient medical","map the inputs into the latent space, which will be utilized for DDI prediction. By including patient medical","history, the model can be extended to perform patient-specific drug safety recommendations.","history, the model can be extended to perform patient-specific drug safety recommendations.",0.9,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,2,2,1
"history, the model can be extended to perform patient-specific drug safety recommendations.","history, the model can be extended to perform patient-specific drug safety recommendations.","based on machine learning, now offer scalable and cost-effective alternatives to identify novel candidate","based on machine learning, now offer scalable and cost-effective alternatives to identify novel candidate",6.85,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,2,2,0
"based on machine learning, now offer scalable and cost-effective alternatives to identify novel candidate","based on machine learning, now offer scalable and cost-effective alternatives to identify novel candidate","interactions, either synergistic or adverse ones, beforehand.","interactions, either synergistic or adverse ones, beforehand.",0.9,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,2,2,1
"interactions, either synergistic or adverse ones, beforehand.","interactions, either synergistic or adverse ones, beforehand.","Recent computational strategies for DDI prediction can be broadly categorized into two paradigms,","Recent computational strategies for DDI prediction can be broadly categorized into two paradigms,",0.9,14.94,0,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,2,2,0
"Recent computational strategies for DDI prediction can be broadly categorized into two paradigms,","Recent computational strategies for DDI prediction can be broadly categorized into two paradigms,","illustrated in Fig. 4: 1 general DDI prediction, which identifies potential interactions across large drug","illustrated in Fig. 4: (1) general DDI prediction, which identifies potential interactions across large drug",0.9,-14.94,0,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,2,2,1
"illustrated in Fig. 4: 1 general DDI prediction, which identifies potential interactions across large drug","illustrated in Fig. 4: (1) general DDI prediction, which identifies potential interactions across large drug","populations; and 2 personalized drug combination recommendation, which tailors treatment regimens by","populations; and (2) personalized drug combination recommendation, which tailors treatment regimens by",0.9,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,2,2,1
"populations; and 2 personalized drug combination recommendation, which tailors treatment regimens by","populations; and (2) personalized drug combination recommendation, which tailors treatment regimens by","further considering individual patient health profiles and personal DDI risk. In this subsection, we will first","further considering individual patient health profiles and personal DDI risk. In this subsection, we will first",0.9,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,2,2,1
"further considering individual patient health profiles and personal DDI risk. In this subsection, we will first","further considering individual patient health profiles and personal DDI risk. In this subsection, we will first","focus on general DDI prediction, and examine commonly used input data types, followed by the discussion","focus on general DDI prediction, and examine commonly used input data types, followed by the discussion",0.9,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,2,2,1
"focus on general DDI prediction, and examine commonly used input data types, followed by the discussion","focus on general DDI prediction, and examine commonly used input data types, followed by the discussion",of recent developments in problem formulations and model architectures. We conclude this subsection with,of recent developments in problem formulations and model architectures. We conclude this subsection with,0.9,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,2,2,1
of recent developments in problem formulations and model architectures. We conclude this subsection with,of recent developments in problem formulations and model architectures. We conclude this subsection with,discussions on personalized drug combination recommendation.,discussions on personalized drug combination recommendation.,0.9,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,2,2,1
5.1 Types of Input Data,Types of Input Data,"Similar to drug–target interaction prediction discussed in the previous section, many early approaches to","Similar to drug–target interaction prediction discussed in the previous section, many early approaches to",3.09,-26.9,0,0,1,11.96,9.96,-1.99,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,3,3,0
"Similar to drug–target interaction prediction discussed in the previous section, many early approaches to","Similar to drug–target interaction prediction discussed in the previous section, many early approaches to","DDI prediction primarily utilized drug–drug interaction graphs, where nodes represent drugs and edges encode their interactions. With advancements in the field, more recent methods have begun to incorporate","code their interactions. With advancements in the field, more recent methods have begun to incorporate",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,3,3,1
"DDI prediction primarily utilized drug–drug interaction graphs, where nodes represent drugs and edges encode their interactions. With advancements in the field, more recent methods have begun to incorporate","code their interactions. With advancements in the field, more recent methods have begun to incorporate","drug molecular structures, represented as molecular graphs as introduced previously, in which nodes denote atoms and edges correspond to chemical bonds. In both types of graphs, nodes and edges are typically","note atoms and edges correspond to chemical bonds. In both types of graphs, nodes and edges are typically",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"drug molecular structures, represented as molecular graphs as introduced previously, in which nodes denote atoms and edges correspond to chemical bonds. In both types of graphs, nodes and edges are typically","note atoms and edges correspond to chemical bonds. In both types of graphs, nodes and edges are typically","enriched with additional features or attributes that capture relevant properties. For example, in drug–drug","enriched with additional features or attributes that capture relevant properties. For example, in drug–drug",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"enriched with additional features or attributes that capture relevant properties. For example, in drug–drug","enriched with additional features or attributes that capture relevant properties. For example, in drug–drug","interaction graphs, node attributes may encode drug-specific properties, while edges can be labeled to indicate interaction types e.g., synergistic or antagonistic effects. In molecular graphs, node features represent","cate interaction types (e.g., synergistic or antagonistic effects). In molecular graphs, node features represent",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"interaction graphs, node attributes may encode drug-specific properties, while edges can be labeled to indicate interaction types e.g., synergistic or antagonistic effects. In molecular graphs, node features represent","cate interaction types (e.g., synergistic or antagonistic effects). In molecular graphs, node features represent","atomic properties, and edge features describe bond characteristics. GNN-based models are capable of processing both graph types, often alongside auxiliary information such as drug similarity matrices, to learn","cessing both graph types, often alongside auxiliary information such as drug similarity matrices, to learn",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"atomic properties, and edge features describe bond characteristics. GNN-based models are capable of processing both graph types, often alongside auxiliary information such as drug similarity matrices, to learn","cessing both graph types, often alongside auxiliary information such as drug similarity matrices, to learn",latent representations from different perspectives and at multiple levels—capturing both relational patterns,latent representations from different perspectives and at multiple levels—capturing both relational patterns,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
latent representations from different perspectives and at multiple levels—capturing both relational patterns,latent representations from different perspectives and at multiple levels—capturing both relational patterns,"in drug interaction networks and structural characteristics at molecular and sub-molecular scales. Increasingly, recent approaches aim to integrate both types of input within a unified learning framework, jointly","ingly, recent approaches aim to integrate both types of input within a unified learning framework, jointly",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"in drug interaction networks and structural characteristics at molecular and sub-molecular scales. Increasingly, recent approaches aim to integrate both types of input within a unified learning framework, jointly","ingly, recent approaches aim to integrate both types of input within a unified learning framework, jointly",capturing topological and structural information to enhance predictive performance.,capturing topological and structural information to enhance predictive performance.,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
capturing topological and structural information to enhance predictive performance.,capturing topological and structural information to enhance predictive performance.,5.2 Problem Formulations,Problem Formulations,5.94,26.9,0,1,0,9.96,11.96,1.99,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,3,3,0
5.2 Problem Formulations,Problem Formulations,The choice of input data and their representations not only inspires model design but also significantly influences problem formulations. Early models primarily focused on drug–drug interaction graphs combined,fluences problem formulations. Early models primarily focused on drug–drug interaction graphs combined,7.01,-26.9,0,0,1,11.96,9.96,-1.99,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,3,3,0
The choice of input data and their representations not only inspires model design but also significantly influences problem formulations. Early models primarily focused on drug–drug interaction graphs combined,fluences problem formulations. Early models primarily focused on drug–drug interaction graphs combined,with simple node-level drug features. Various GNN architectures were employed to learn low-dimensional,with simple node-level drug features. Various GNN architectures were employed to learn low-dimensional,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
with simple node-level drug features. Various GNN architectures were employed to learn low-dimensional,with simple node-level drug features. Various GNN architectures were employed to learn low-dimensional,"representations of drugs from these graphs 97, 98. Building on this idea, models such as GCNMK 36","representations of drugs from these graphs [97, 98]. Building on this idea, models such as GCNMK [36]",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"representations of drugs from these graphs 97, 98. Building on this idea, models such as GCNMK 36","representations of drugs from these graphs [97, 98]. Building on this idea, models such as GCNMK [36]","further decomposed the DDI graph into two separate graphs, one representing interactions where a drug increases the activity of another, and the other where it decreases activity, and applied two GNNs to learn drug","creases the activity of another, and the other where it decreases activity, and applied two GNNs to learn drug",4.92,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"further decomposed the DDI graph into two separate graphs, one representing interactions where a drug increases the activity of another, and the other where it decreases activity, and applied two GNNs to learn drug","creases the activity of another, and the other where it decreases activity, and applied two GNNs to learn drug","representations from these differentiated views. Subsequent studies expanded the input space by incorporating drug molecular graphs, thereby enabling the integration of both structural and relational perspectives","rating drug molecular graphs, thereby enabling the integration of both structural and relational perspectives",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"representations from these differentiated views. Subsequent studies expanded the input space by incorporating drug molecular graphs, thereby enabling the integration of both structural and relational perspectives","rating drug molecular graphs, thereby enabling the integration of both structural and relational perspectives","to enhance model performance. For instance, MRCGNN 39 employed a GNN to process the relational","to enhance model performance. For instance, MRCGNN [39] employed a GNN to process the relational",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"to enhance model performance. For instance, MRCGNN 39 employed a GNN to process the relational","to enhance model performance. For instance, MRCGNN [39] employed a GNN to process the relational",DDI graph while enriching each drug’s feature representation with molecular-level information extracted by,DDI graph while enriching each drug’s feature representation with molecular-level information extracted by,1,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,3,3,1
DDI graph while enriching each drug’s feature representation with molecular-level information extracted by,DDI graph while enriching each drug’s feature representation with molecular-level information extracted by,a separate GNN operating on its molecular graph. This multimodal approach allowed the model to simultaneously capture both chemical and interaction-level knowledge.,a separate GNN operating on its molecular graph. This multimodal approach allowed the model to simulta-,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
a separate GNN operating on its molecular graph. This multimodal approach allowed the model to simultaneously capture both chemical and interaction-level knowledge.,a separate GNN operating on its molecular graph. This multimodal approach allowed the model to simulta-,The evolution of problem formulation also extends to the design of prediction tasks. Some models,The evolution of problem formulation also extends to the design of prediction tasks. Some models,4.92,14.94,0,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,3,3,0
The evolution of problem formulation also extends to the design of prediction tasks. Some models,The evolution of problem formulation also extends to the design of prediction tasks. Some models,"framed DDI prediction as a binary classification problem, aiming solely to determine the existence of an","framed DDI prediction as a binary classification problem, aiming solely to determine the existence of an",1,-14.94,0,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"framed DDI prediction as a binary classification problem, aiming solely to determine the existence of an","framed DDI prediction as a binary classification problem, aiming solely to determine the existence of an","interaction 98. Others formulated it as a multi-label classification task, predicting both the presence and","interaction [98]. Others formulated it as a multi-label classification task, predicting both the presence and",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"interaction 98. Others formulated it as a multi-label classification task, predicting both the presence and","interaction [98]. Others formulated it as a multi-label classification task, predicting both the presence and","the specific type of interaction from a predefined label set 99, 100, 101, 102. Many researchers have","the specific type of interaction from a predefined label set [99, 100, 101, 102]. Many researchers have",1,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"the specific type of interaction from a predefined label set 99, 100, 101, 102. Many researchers have","the specific type of interaction from a predefined label set [99, 100, 101, 102]. Many researchers have","further distinguished between adverse DDI prediction 103, 104, 105 and drug combination or synergy","further distinguished between adverse DDI prediction [103, 104, 105] and drug combination or synergy",1,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"further distinguished between adverse DDI prediction 103, 104, 105 and drug combination or synergy","further distinguished between adverse DDI prediction [103, 104, 105] and drug combination or synergy","prediction 106, 105, 107, 108, providing a more nuanced understanding of interaction consequences.","prediction [106, 105, 107, 108], providing a more nuanced understanding of interaction consequences.",1,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"prediction 106, 105, 107, 108, providing a more nuanced understanding of interaction consequences.","prediction [106, 105, 107, 108], providing a more nuanced understanding of interaction consequences.","Overall, advancements in problem formulation aim to enrich input representations with biologically","Overall, advancements in problem formulation aim to enrich input representations with biologically",1,14.94,0,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,3,3,0
"Overall, advancements in problem formulation aim to enrich input representations with biologically","Overall, advancements in problem formulation aim to enrich input representations with biologically","meaningful information and to enable more fine-grained, application-specific predictions. Future directions","meaningful information and to enable more fine-grained, application-specific predictions. Future directions",1,-14.94,0,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"meaningful information and to enable more fine-grained, application-specific predictions. Future directions","meaningful information and to enable more fine-grained, application-specific predictions. Future directions",are likely to emphasize input data that better reflect the underlying biological complexity of DDIs. For the,are likely to emphasize input data that better reflect the underlying biological complexity of DDIs. For the,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
are likely to emphasize input data that better reflect the underlying biological complexity of DDIs. For the,are likely to emphasize input data that better reflect the underlying biological complexity of DDIs. For the,"prediction outcomes, knowledge of specific side effects from adverse interaction prediction and information","prediction outcomes, knowledge of specific side effects from adverse interaction prediction and information",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"prediction outcomes, knowledge of specific side effects from adverse interaction prediction and information","prediction outcomes, knowledge of specific side effects from adverse interaction prediction and information",of targeted diseases in drug combination modeling are welcome additions.,of targeted diseases in drug combination modeling are welcome additions.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
of targeted diseases in drug combination modeling are welcome additions.,of targeted diseases in drug combination modeling are welcome additions.,5.3 Advancements in Model Structure,Advancements in Model Structure,5.94,26.9,0,0,0,9.96,11.96,1.99,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,3,3,0
5.3 Advancements in Model Structure,Advancements in Model Structure,"Beyond problem formulation, significant research has focused on improving model architectures to more effectively aggregate information across different data modalities and drug representations. These approaches",fectively aggregate information across different data modalities and drug representations. These approaches,7.01,-26.9,0,0,1,11.96,9.96,-1.99,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,3,3,0
"typically employ distinct architectures e.g., GNNs, CNNs for different modalities or representations, and","typically employ distinct architectures (e.g., GNNs, CNNs) for different modalities or representations, and","combine their learned features using various fusion strategies. Earlier models such as MDNN 37, GCNMK 36, MRCGNN 39, and DeepDDS 107 fused features from each modality or representation","NMK [36], MRCGNN [39], and DeepDDS [107] fused features from each modality or representation",4.92,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"combine their learned features using various fusion strategies. Earlier models such as MDNN 37, GCNMK 36, MRCGNN 39, and DeepDDS 107 fused features from each modality or representation","NMK [36], MRCGNN [39], and DeepDDS [107] fused features from each modality or representation","through simple concatenation. While this strategy preserves feature information from all modalities, it neither accounts for the relative importance of each data source nor captures potential inter-modal relationships.",ther accounts for the relative importance of each data source nor captures potential inter-modal relationships.,4.92,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"through simple concatenation. While this strategy preserves feature information from all modalities, it neither accounts for the relative importance of each data source nor captures potential inter-modal relationships.",ther accounts for the relative importance of each data source nor captures potential inter-modal relationships.,"To address these limitations, more recent models have incorporated attention mechanisms to fuse latent","To address these limitations, more recent models have incorporated attention mechanisms to fuse latent",1,14.94,0,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,4,4,0
"To address these limitations, more recent models have incorporated attention mechanisms to fuse latent","To address these limitations, more recent models have incorporated attention mechanisms to fuse latent","features from different modalities, or from different drugs within the same modality, via cross-attention. For","features from different modalities, or from different drugs within the same modality, via cross-attention. For",1,-14.94,0,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"features from different modalities, or from different drugs within the same modality, via cross-attention. For","features from different modalities, or from different drugs within the same modality, via cross-attention. For","instance, SSF-DDI 109 utilized two drug representations: the 1D SMILES sequence and the 2D graph","instance, SSF-DDI [109] utilized two drug representations: the 1D SMILES sequence and the 2D graph",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"instance, SSF-DDI 109 utilized two drug representations: the 1D SMILES sequence and the 2D graph","instance, SSF-DDI [109] utilized two drug representations: the 1D SMILES sequence and the 2D graph","structure. Separate architectures CNN for SMILES and GNN for molecular graphs were used, and a crossattention mechanism was employed to integrate the latent features generated by the two models. Similarly,","attention mechanism was employed to integrate the latent features generated by the two models. Similarly,",4.92,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"structure. Separate architectures CNN for SMILES and GNN for molecular graphs were used, and a crossattention mechanism was employed to integrate the latent features generated by the two models. Similarly,","attention mechanism was employed to integrate the latent features generated by the two models. Similarly,",SRR-DDI 110 constructed 2D molecular graph representations for drug pairs and applied cross-attention,SRR-DDI [110] constructed 2D molecular graph representations for drug pairs and applied cross-attention,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,4,4,1
SRR-DDI 110 constructed 2D molecular graph representations for drug pairs and applied cross-attention,SRR-DDI [110] constructed 2D molecular graph representations for drug pairs and applied cross-attention,to fuse the learned latent features of the two drugs.,to fuse the learned latent features of the two drugs.,1,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
to fuse the learned latent features of the two drugs.,to fuse the learned latent features of the two drugs.,MD-Syn 111 proposed a multi-modal architecture with both one-dimensional and two-dimensional,MD-Syn [111] proposed a multi-modal architecture with both one-dimensional and two-dimensional,1,14.94,0,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,4,4,0
MD-Syn 111 proposed a multi-modal architecture with both one-dimensional and two-dimensional,MD-Syn [111] proposed a multi-modal architecture with both one-dimensional and two-dimensional,"feature embedding modules, which allows incorporation of SMILES sequences, cell line information, drug","feature embedding modules, which allows incorporation of SMILES sequences, cell line information, drug",1,-14.94,0,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"feature embedding modules, which allows incorporation of SMILES sequences, cell line information, drug","feature embedding modules, which allows incorporation of SMILES sequences, cell line information, drug","molecular graphs, and protein–protein interaction PPI networks. Rather than using cross-attention, MDSyn introduced a graph-trans pooling module within the 2D-feature embedding module, employing Transformer encoder layers with multi-head self-attention to process the concatenated latent representations from",former encoder layers with multi-head self-attention to process the concatenated latent representations from,8.84,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"molecular graphs, and protein–protein interaction PPI networks. Rather than using cross-attention, MDSyn introduced a graph-trans pooling module within the 2D-feature embedding module, employing Transformer encoder layers with multi-head self-attention to process the concatenated latent representations from",former encoder layers with multi-head self-attention to process the concatenated latent representations from,the PPI network and drug graphs.,the PPI network and drug graphs.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
the PPI network and drug graphs.,the PPI network and drug graphs.,Another direction in architectural advancement focuses on multi-level feature aggregation across GNN,Another direction in architectural advancement focuses on multi-level feature aggregation across GNN,1,14.94,0,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,4,4,0
Another direction in architectural advancement focuses on multi-level feature aggregation across GNN,Another direction in architectural advancement focuses on multi-level feature aggregation across GNN,"layers, particularly for molecular graphs. For example, DAS-DDI 112 introduced weighted layer-wise","layers, particularly for molecular graphs. For example, DAS-DDI [112] introduced weighted layer-wise",1,-14.94,0,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"layers, particularly for molecular graphs. For example, DAS-DDI 112 introduced weighted layer-wise","layers, particularly for molecular graphs. For example, DAS-DDI [112] introduced weighted layer-wise","aggregation, where each GNN layer contributes differently to the final embedding. This enables molecular","aggregation, where each GNN layer contributes differently to the final embedding. This enables molecular",1,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"aggregation, where each GNN layer contributes differently to the final embedding. This enables molecular","aggregation, where each GNN layer contributes differently to the final embedding. This enables molecular","substructures of varying granularity to inform the final drug representation, thereby enhancing the expressiveness and robustness of the model in capturing complex inter-drug relationships.",siveness and robustness of the model in capturing complex inter-drug relationships.,4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"substructures of varying granularity to inform the final drug representation, thereby enhancing the expressiveness and robustness of the model in capturing complex inter-drug relationships.",siveness and robustness of the model in capturing complex inter-drug relationships.,5.4 Personalized Drug Combination Recommendation,Personalized Drug Combination Recommendation,5.78,26.9,0,1,0,9.96,11.96,1.99,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,4,4,0
5.4 Personalized Drug Combination Recommendation,Personalized Drug Combination Recommendation,A distinct line of research focuses on personalized DDI prediction by incorporating patient-specific medical,A distinct line of research focuses on personalized DDI prediction by incorporating patient-specific medical,3.09,-26.9,0,0,1,11.96,9.96,-1.99,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,4,4,0
A distinct line of research focuses on personalized DDI prediction by incorporating patient-specific medical,A distinct line of research focuses on personalized DDI prediction by incorporating patient-specific medical,histories. These models are less common due to the fact that data privacy concerns hinder the availability,histories. These models are less common due to the fact that data privacy concerns hinder the availability,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
histories. These models are less common due to the fact that data privacy concerns hinder the availability,histories. These models are less common due to the fact that data privacy concerns hinder the availability,"of clinical data, but they offer unique insights. For instance, SafeDrug 40 used GNNs and RNNs to align","of clinical data, but they offer unique insights. For instance, SafeDrug [40] used GNNs and RNNs to align",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"of clinical data, but they offer unique insights. For instance, SafeDrug 40 used GNNs and RNNs to align","of clinical data, but they offer unique insights. For instance, SafeDrug [40] used GNNs and RNNs to align","molecular features with patient treatment histories, producing compatibility scores for candidate drug combinations. MoleRec 41 leveraged attention mechanisms to integrate patient records and drug representations",nations. MoleRec [41] leveraged attention mechanisms to integrate patient records and drug representations,4.92,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"molecular features with patient treatment histories, producing compatibility scores for candidate drug combinations. MoleRec 41 leveraged attention mechanisms to integrate patient records and drug representations",nations. MoleRec [41] leveraged attention mechanisms to integrate patient records and drug representations,for safe prescription generation.,for safe prescription generation.,1,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
for safe prescription generation.,for safe prescription generation.,"Despite their promise, challenges remain. GNNs often generate nearly identical embeddings for structurally similar molecules, regardless of therapeutic context. Carmen 42 addressed this with a contextaware GNN that incorporated medication context during atom-level message aggregation. This architecture",aware GNN that incorporated medication context during atom-level message aggregation. This architecture,8.84,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,4,4,0
"Despite their promise, challenges remain. GNNs often generate nearly identical embeddings for structurally similar molecules, regardless of therapeutic context. Carmen 42 addressed this with a contextaware GNN that incorporated medication context during atom-level message aggregation. This architecture",aware GNN that incorporated medication context during atom-level message aggregation. This architecture,"produced distinct embeddings based on therapeutic relevance, offering a refined strategy for personalized","produced distinct embeddings based on therapeutic relevance, offering a refined strategy for personalized",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"produced distinct embeddings based on therapeutic relevance, offering a refined strategy for personalized","produced distinct embeddings based on therapeutic relevance, offering a refined strategy for personalized","drug combination recommendations. These models incorporating personal information represent a significant step toward safer, more effective treatment planning, highlighting the value of integrating biomedical","cant step toward safer, more effective treatment planning, highlighting the value of integrating biomedical",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
"drug combination recommendations. These models incorporating personal information represent a significant step toward safer, more effective treatment planning, highlighting the value of integrating biomedical","cant step toward safer, more effective treatment planning, highlighting the value of integrating biomedical",knowledge with patient-specific data.,knowledge with patient-specific data.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
knowledge with patient-specific data.,knowledge with patient-specific data.,"Finally, for easy reference, all the approaches discussed in this review for all the three tasks are organized","Finally, for easy reference, all the approaches discussed in this review for all the three tasks are organized",1,14.94,0,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,4,4,0
"Finally, for easy reference, all the approaches discussed in this review for all the three tasks are organized","Finally, for easy reference, all the approaches discussed in this review for all the three tasks are organized",in Table 1.,in Table 1.,1,-14.94,0,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
in Table 1.,in Table 1.,6 Benchmark Databases,Benchmark Databases,6.91,21.52,0,0,0,9.96,14.35,4.38,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,4,4,0
6 Benchmark Databases,Benchmark Databases,"In addition to newly developed methodologies, benchmark datasets play a vital role in advancing the field of","In addition to newly developed methodologies, benchmark datasets play a vital role in advancing the field of",4.1,-21.52,0,0,1,14.35,9.96,-4.38,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,4,4,0
"In addition to newly developed methodologies, benchmark datasets play a vital role in advancing the field of","In addition to newly developed methodologies, benchmark datasets play a vital role in advancing the field of",computational drug discovery. High-quality data is essential for all the tasks ranging from molecular design,computational drug discovery. High-quality data is essential for all the tasks ranging from molecular design,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,4,4,1
Table 1: GNN-based models discussed in this review and their characteristics. Each row includes the name,Table 1: GNN-based models discussed in this review and their characteristics. Each row includes the name,"of the approach, the main model architecture, the prediction task and the datasets used. The approaches","of the approach, the main model architecture, the prediction task and the datasets used. The approaches",1.84,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"of the approach, the main model architecture, the prediction task and the datasets used. The approaches","of the approach, the main model architecture, the prediction task and the datasets used. The approaches",are grouped into different bucket based on their tasks. The background with yellow color indicates that the,are grouped into different bucket based on their tasks. The background with yellow color indicates that the,1.84,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
are grouped into different bucket based on their tasks. The background with yellow color indicates that the,are grouped into different bucket based on their tasks. The background with yellow color indicates that the,approaches primarily utilized 2D structure and the blue color indicates that the approaches primarily utilized,approaches primarily utilized 2D structure and the blue color indicates that the approaches primarily utilized,1.84,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
approaches primarily utilized 2D structure and the blue color indicates that the approaches primarily utilized,approaches primarily utilized 2D structure and the blue color indicates that the approaches primarily utilized,3D structure. Methods using pre-training are labeled with ? and methods using few-shot learning are labeled,3D structure. Methods using pre-training are labeled with ?and methods using few-shot learning are labeled,1.84,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,5,5,1
3D structure. Methods using pre-training are labeled with ? and methods using few-shot learning are labeled,3D structure. Methods using pre-training are labeled with ?and methods using few-shot learning are labeled,with ? .,with ?.,1.84,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
with ? .,with ?.,Name architecture Task Datasets,architecture,1.11,53.16,0,0,0,9.96,5.05,-4.92,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,5,5,1
Name architecture Task Datasets,architecture,"ConfVAE 6 MPNN Unconstrained Generation w/ CVAE and uses 2D&3D GEOM-QM9, GEOM-Drugs",Unconstrained Generation w/ CVAE and uses 2D&3D,2.72,33.12,0,0,0,5.05,5.05,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"ConfVAE 6 MPNN Unconstrained Generation w/ CVAE and uses 2D&3D GEOM-QM9, GEOM-Drugs",Unconstrained Generation w/ CVAE and uses 2D&3D,"VonMisesNet 7 GCN Unconstrained Generation w/ Von Mises distribution NMRShiftDB, GDB-17",Unconstrained Generation w/ Von Mises distribution,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"VonMisesNet 7 GCN Unconstrained Generation w/ Von Mises distribution NMRShiftDB, GDB-17",Unconstrained Generation w/ Von Mises distribution,MoLeR 8 GNN Constrained Generation w/ motifs-based substructures GuacaMol,Constrained Generation w/ motifs-based substructures,2.7,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
MoLeR 8 GNN Constrained Generation w/ motifs-based substructures GuacaMol,Constrained Generation w/ motifs-based substructures,"MiCam 9 GNN Constrained Generation w/ connection-aware motif vocabulary QM9, ZINC, GuacaMol",Constrained Generation w/ connection-aware motif vocabulary,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"MiCam 9 GNN Constrained Generation w/ connection-aware motif vocabulary QM9, ZINC, GuacaMol",Constrained Generation w/ connection-aware motif vocabulary,GEAM 10 MPNN Constrained Generation w/ soft-actor critic ZINC250k,Constrained Generation w/ soft-actor critic,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
GEAM 10 MPNN Constrained Generation w/ soft-actor critic ZINC250k,Constrained Generation w/ soft-actor critic,AR 11 GNN Ligand-Protein Based Generation w/ auxiliary network CrossDocked,Ligand-Protein Based Generation w/ auxiliary network,2.7,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
AR 11 GNN Ligand-Protein Based Generation w/ auxiliary network CrossDocked,Ligand-Protein Based Generation w/ auxiliary network,GraphBP 12 GNN Ligand-Protein Based Generation w/ spherical coordinates CrossDocked,Ligand-Protein Based Generation w/ spherical coordinates,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
GraphBP 12 GNN Ligand-Protein Based Generation w/ spherical coordinates CrossDocked,Ligand-Protein Based Generation w/ spherical coordinates,Pocket2Mol 13 GNN Ligand-Protein Based Generation w/ auxiliary atom positioning CrossDocked,Ligand-Protein Based Generation w/ auxiliary atom positioning,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
Pocket2Mol 13 GNN Ligand-Protein Based Generation w/ auxiliary atom positioning CrossDocked,Ligand-Protein Based Generation w/ auxiliary atom positioning,FLAG 14 GNN Ligand-Protein Based Generation w/ auxiliary motif attachment CrossDocked,Ligand-Protein Based Generation w/ auxiliary motif attachment,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
FLAG 14 GNN Ligand-Protein Based Generation w/ auxiliary motif attachment CrossDocked,Ligand-Protein Based Generation w/ auxiliary motif attachment,SQUID 15 GNN Ligand-Protein Based Generation w/ 3-D shape MOSES,Ligand-Protein Based Generation w/ 3-D shape,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
SQUID 15 GNN Ligand-Protein Based Generation w/ 3-D shape MOSES,Ligand-Protein Based Generation w/ 3-D shape,"NeurTN 17 GNN Property Prediction w/ powerful nonlinear relationships CTD,DrugBank,UniProt4",Property Prediction w/ powerful nonlinear relationships,2.7,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"NeurTN 17 GNN Property Prediction w/ powerful nonlinear relationships CTD,DrugBank,UniProt4",Property Prediction w/ powerful nonlinear relationships,"PhysChem 22 MPNN Property Prediction w/ physical&chemical information QM7,QM8,QM9,Lipop,FreeSolv,ESOL,COVID19",Property Prediction w/ physical&chemical information,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"PhysChem 22 MPNN Property Prediction w/ physical&chemical information QM7,QM8,QM9,Lipop,FreeSolv,ESOL,COVID19",Property Prediction w/ physical&chemical information,"O-GNN 23 GNN Property Prediction w/ ring substructures BBBP,Tox21,ClinTox,HIV,BACE,SIDER,FS-Mol",Property Prediction w/ ring substructures,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"O-GNN 23 GNN Property Prediction w/ ring substructures BBBP,Tox21,ClinTox,HIV,BACE,SIDER,FS-Mol",Property Prediction w/ ring substructures,"MoleOOD 71 SAGE Property Prediction w/ invariant substructure across environments BACE,BBBP,SIDER,HIV,DrugOOD",Property Prediction w/ invariant substructure across environments,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"MoleOOD 71 SAGE Property Prediction w/ invariant substructure across environments BACE,BBBP,SIDER,HIV,DrugOOD",Property Prediction w/ invariant substructure across environments,"MGSSL 63 GNN ? Property Prediction w/ motif-based self-supervised learning MUV,ClinTox,SIDER,HIV,Tox21,BACE,",Property Prediction w/ motif-based self-supervised learning,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"MGSSL 63 GNN ? Property Prediction w/ motif-based self-supervised learning MUV,ClinTox,SIDER,HIV,Tox21,BACE,",Property Prediction w/ motif-based self-supervised learning,"ToxCast,BBBP","ToxCast,BBBP",1,221.44,0,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"ToxCast,BBBP","ToxCast,BBBP","MoCL 18 GIN ? Property Prediction w/ knowledge-aware contrastive learning BACE,BBBP,ClinTox,Mutag,SIDER,Tox21,ToxCast",Property Prediction w/ knowledge-aware contrastive learning,1,-221.44,0,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"MoCL 18 GIN ? Property Prediction w/ knowledge-aware contrastive learning BACE,BBBP,ClinTox,Mutag,SIDER,Tox21,ToxCast",Property Prediction w/ knowledge-aware contrastive learning,"KCL 64 MPNN ? Property Prediction w/ domain knowledge contrastive learning BBBP,Tox21,ToxCast,SIDER,ClinTox,BACE,",Property Prediction w/ domain knowledge contrastive learning,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"KCL 64 MPNN ? Property Prediction w/ domain knowledge contrastive learning BBBP,Tox21,ToxCast,SIDER,ClinTox,BACE,",Property Prediction w/ domain knowledge contrastive learning,"ESOL,FreeSolv","ESOL,FreeSolv",1,221.44,0,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"ESOL,FreeSolv","ESOL,FreeSolv","MCHNN 65 GCN ? Property Prediction w/ multi-view contrastive learning PubChem,MDAD,DrugVirus,HMDAD,Disbiome,",Property Prediction w/ multi-view contrastive learning,1,-221.44,0,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"MCHNN 65 GCN ? Property Prediction w/ multi-view contrastive learning PubChem,MDAD,DrugVirus,HMDAD,Disbiome,",Property Prediction w/ multi-view contrastive learning,"gutMDisorder,Peryton","gutMDisorder,Peryton",1,221.44,0,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,5,5,1
"gutMDisorder,Peryton","gutMDisorder,Peryton","HiMol 66 GNN ? Property Prediction w/ boundaries self-supervised learning BACE,BBBP,Tox21,ToxCast,SIDER,ClinTox,",Property Prediction w/ boundaries self-supervised learning,1,-221.44,0,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"HiMol 66 GNN ? Property Prediction w/ boundaries self-supervised learning BACE,BBBP,Tox21,ToxCast,SIDER,ClinTox,",Property Prediction w/ boundaries self-supervised learning,"ESOL,FreeSolv,Lipop,QM7,QM8,QM9","ESOL,FreeSolv,Lipop,QM7,QM8,QM9",1,221.44,0,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"ESOL,FreeSolv,Lipop,QM7,QM8,QM9","ESOL,FreeSolv,Lipop,QM7,QM8,QM9","HSL-RG 19 GNN ?? Property Prediction w/ few-shot learning&self-supervised learning Tox21,SIDER,MUV,ToxCast",Property Prediction w/ few-shot learning&self-supervised learning,1,-221.44,0,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"HSL-RG 19 GNN ?? Property Prediction w/ few-shot learning&self-supervised learning Tox21,SIDER,MUV,ToxCast",Property Prediction w/ few-shot learning&self-supervised learning,MHNfs 68 GNN ? Property Prediction w/ few-shot learning&context module FS-Mol,Property Prediction w/ few-shot learning&context module,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
MHNfs 68 GNN ? Property Prediction w/ few-shot learning&context module FS-Mol,Property Prediction w/ few-shot learning&context module,"GS-Meta 69 GNN ? Property Prediction w/ few-shot learning&simultaneous multiple labels Tox21,SIDER,MUV,ToxCast,PCBA",Property Prediction w/ few-shot learning&simultaneous multiple labels,1,0,1,0,1,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"GS-Meta 69 GNN ? Property Prediction w/ few-shot learning&simultaneous multiple labels Tox21,SIDER,MUV,ToxCast,PCBA",Property Prediction w/ few-shot learning&simultaneous multiple labels,"PACIA 20 GNN ?? Property Prediction w/ few-shot learning&adaptive parameters Tox21,SIDER,MUV,ToxCast,FS-Mol",Property Prediction w/ few-shot learning&adaptive parameters,1,0,1,1,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"PACIA 20 GNN ?? Property Prediction w/ few-shot learning&adaptive parameters Tox21,SIDER,MUV,ToxCast,FS-Mol",Property Prediction w/ few-shot learning&adaptive parameters,"Geo-DEG 70 MPNN Property Prediction w/ hierarchical molecular grammar CROW,Permeability,FreeSolv,Lipop,HOPV,PTC,ClinTox",Property Prediction w/ hierarchical molecular grammar,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"Geo-DEG 70 MPNN Property Prediction w/ hierarchical molecular grammar CROW,Permeability,FreeSolv,Lipop,HOPV,PTC,ClinTox",Property Prediction w/ hierarchical molecular grammar,"DVMP 73 GCN ? Property Prediction w/ pre-train for dual-view 1D&2D molecule BBBP,Tox21,ClinTox,HIV,BACE,SIDER,ESOL",Property Prediction w/ pre-train for dual-view 1D&2D molecule,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"DVMP 73 GCN ? Property Prediction w/ pre-train for dual-view 1D&2D molecule BBBP,Tox21,ClinTox,HIV,BACE,SIDER,ESOL",Property Prediction w/ pre-train for dual-view 1D&2D molecule,"GraphMVP 75 GNN ? Property Prediction w/ pre-train consistency between 2D&3D BBBP,Tox21,ToxCast,SIDER,MUV,HIV,BACE",Property Prediction w/ pre-train consistency between 2D&3D,2.7,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"GraphMVP 75 GNN ? Property Prediction w/ pre-train consistency between 2D&3D BBBP,Tox21,ToxCast,SIDER,MUV,HIV,BACE",Property Prediction w/ pre-train consistency between 2D&3D,SphereNet 45 MPNN Property Prediction w/ spherical message passing QM9,Property Prediction w/ spherical message passing,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
SphereNet 45 MPNN Property Prediction w/ spherical message passing QM9,Property Prediction w/ spherical message passing,"UnifiedPML 76 GN Blocks ? Property Prediction w/ pre-train on multi-tasks for 2D&3D BBBP,Tox21,ClinTox,HIV,BACE,SIDER",Property Prediction w/ pre-train on multi-tasks for 2D&3D,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"UnifiedPML 76 GN Blocks ? Property Prediction w/ pre-train on multi-tasks for 2D&3D BBBP,Tox21,ClinTox,HIV,BACE,SIDER",Property Prediction w/ pre-train on multi-tasks for 2D&3D,"GeomGCL 77 MPNN ? Property Prediction w/ dual-channel message passing for 2D&3D ClinTox,SIDER,Tox21,ToxCast,ESOL,FreeSolv,Lipop",Property Prediction w/ dual-channel message passing for 2D&3D,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"GeomGCL 77 MPNN ? Property Prediction w/ dual-channel message passing for 2D&3D ClinTox,SIDER,Tox21,ToxCast,ESOL,FreeSolv,Lipop",Property Prediction w/ dual-channel message passing for 2D&3D,MolKGNN 74 GNN Property Prediction w/ molecular chirality PubChem,Property Prediction w/ molecular chirality,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
MolKGNN 74 GNN Property Prediction w/ molecular chirality PubChem,Property Prediction w/ molecular chirality,"3D-Informax 30 MPNN ? Property Prediction w/ transfer learning for 2D&3D QM9,GEOM-Drugs",Property Prediction w/ transfer learning for 2D&3D,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"3D-Informax 30 MPNN ? Property Prediction w/ transfer learning for 2D&3D QM9,GEOM-Drugs",Property Prediction w/ transfer learning for 2D&3D,"MoleculeSDE 78 GNN ? Property Prediction w/ multi-modal pre-train for 2D&3D BBBP,Tox21,ToxCast,SIDER,ClinTox,MUV,HIV,BACE",Property Prediction w/ multi-modal pre-train for 2D&3D,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"MoleculeSDE 78 GNN ? Property Prediction w/ multi-modal pre-train for 2D&3D BBBP,Tox21,ToxCast,SIDER,ClinTox,MUV,HIV,BACE",Property Prediction w/ multi-modal pre-train for 2D&3D,"3D-PGT 79 GNN ? Property Prediction w/ multi-task generative pre-train on 3D BBBP,Tox21,ToxCast,SIDER,ClinTox,MUV,",Property Prediction w/ multi-task generative pre-train on 3D,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"3D-PGT 79 GNN ? Property Prediction w/ multi-task generative pre-train on 3D BBBP,Tox21,ToxCast,SIDER,ClinTox,MUV,",Property Prediction w/ multi-task generative pre-train on 3D,"HIV,BACE,ESOL,Lipop,Malaria,CEP,Davis,KIBA","HIV,BACE,ESOL,Lipop,Malaria,CEP,Davis,KIBA",1,221.44,0,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"HIV,BACE,ESOL,Lipop,Malaria,CEP,Davis,KIBA","HIV,BACE,ESOL,Lipop,Malaria,CEP,Davis,KIBA","MGraphDTA 27 GNN Molecular Interactions Prediction w/ super-deep GNN Davis,KIBA,Metz,Human,C. elegans,ToxCast",Molecular Interactions Prediction w/ super-deep GNN,2.7,-221.44,0,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"MGraphDTA 27 GNN Molecular Interactions Prediction w/ super-deep GNN Davis,KIBA,Metz,Human,C. elegans,ToxCast",Molecular Interactions Prediction w/ super-deep GNN,"CGIB 28 MPNN Molecular Interactions Prediction w/ substructure information MNSol,FreeSolv,CompSol,Abraham,CombiSolv",Molecular Interactions Prediction w/ substructure information,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"CGIB 28 MPNN Molecular Interactions Prediction w/ substructure information MNSol,FreeSolv,CompSol,Abraham,CombiSolv",Molecular Interactions Prediction w/ substructure information,SG-CNN 24 GNN Binding Affinity Prediction w/ complementary representations PDBbind,Binding Affinity Prediction w/ complementary representations,2.7,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
SG-CNN 24 GNN Binding Affinity Prediction w/ complementary representations PDBbind,Binding Affinity Prediction w/ complementary representations,IGN 80 GNN Binding Affinity Prediction w/ chemical information PDBbind,Binding Affinity Prediction w/ chemical information,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
IGN 80 GNN Binding Affinity Prediction w/ chemical information PDBbind,Binding Affinity Prediction w/ chemical information,"MP-GNN 81 GNN Binding Affinity Prediction w/ multiphysical representations PDBbind,SARS-CoV BA",Binding Affinity Prediction w/ multiphysical representations,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"MP-GNN 81 GNN Binding Affinity Prediction w/ multiphysical representations PDBbind,SARS-CoV BA",Binding Affinity Prediction w/ multiphysical representations,GraphscoreDTA 82 GNN Binding Affinity Prediction w/ bitransport information PDBbind,Binding Affinity Prediction w/ bitransport information,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
GraphscoreDTA 82 GNN Binding Affinity Prediction w/ bitransport information PDBbind,Binding Affinity Prediction w/ bitransport information,NERE 25 MPNN ? Binding Affinity Prediction w/ Neural Euler’s Rotation Equations PDBbind,Binding Affinity Prediction w/ Neural Euler’s Rotation Equations,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
NERE 25 MPNN ? Binding Affinity Prediction w/ Neural Euler’s Rotation Equations PDBbind,Binding Affinity Prediction w/ Neural Euler’s Rotation Equations,E3Bind 26 GIN Binding Affinity Prediction w/ docking PDBbind,Binding Affinity Prediction w/ docking,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
E3Bind 26 GIN Binding Affinity Prediction w/ docking PDBbind,Binding Affinity Prediction w/ docking,FABind 83 GCN Binding Affinity Prediction w/ pocket prediction and docking PDBbind,Binding Affinity Prediction w/ pocket prediction and docking,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
FABind 83 GCN Binding Affinity Prediction w/ pocket prediction and docking PDBbind,Binding Affinity Prediction w/ pocket prediction and docking,NeuralMD 84 MPNN Protein-Ligand Binding Dynamics Simulations MISATO,Protein-Ligand Binding Dynamics Simulations,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
NeuralMD 84 MPNN Protein-Ligand Binding Dynamics Simulations MISATO,Protein-Ligand Binding Dynamics Simulations,"EquiPocket 85 GNN Ligand Binding Site Prediction w/ geometric and chemical scPDB,PDBbind,COACH420,HOLO4K",Ligand Binding Site Prediction w/ geometric and chemical,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"EquiPocket 85 GNN Ligand Binding Site Prediction w/ geometric and chemical scPDB,PDBbind,COACH420,HOLO4K",Ligand Binding Site Prediction w/ geometric and chemical,MDNN 37 GNN DDI Prediction w/ knowledge graphs DrugBank,DDI Prediction w/ knowledge graphs,2.7,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
MDNN 37 GNN DDI Prediction w/ knowledge graphs DrugBank,DDI Prediction w/ knowledge graphs,"DPDDI 98 GCN DDI prediction w/ extraction of the network structure features of drugs from DDI network DrugBank,ZhangDDI",DDI prediction w/ extraction of the network structure features of drugs from DDI network,1,0,1,0,1,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"DPDDI 98 GCN DDI prediction w/ extraction of the network structure features of drugs from DDI network DrugBank,ZhangDDI",DDI prediction w/ extraction of the network structure features of drugs from DDI network,GCNMK 36 GCN DDI Prediction w/ dual-block GNN DrugBank,DDI Prediction w/ dual-block GNN,1,0,1,1,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
GCNMK 36 GCN DDI Prediction w/ dual-block GNN DrugBank,DDI Prediction w/ dual-block GNN,"MRCGNN 39 GCN DDI Prediction w/ incorporation of negative DDI event Deng’s dataset,Ryu’s dataset",DDI Prediction w/ incorporation of negative DDI event,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"MRCGNN 39 GCN DDI Prediction w/ incorporation of negative DDI event Deng’s dataset,Ryu’s dataset",DDI Prediction w/ incorporation of negative DDI event,"SRR-DDI 110 MPNN DDI Prediction w/ self-attention mechanism DrugBank,Twosides",DDI Prediction w/ self-attention mechanism,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"SRR-DDI 110 MPNN DDI Prediction w/ self-attention mechanism DrugBank,Twosides",DDI Prediction w/ self-attention mechanism,"DAS-DDI 112 GCN DDI Prediction w/ dual-view framework DrugBank,ChChMiner,ZhangDDI",DDI Prediction w/ dual-view framework,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"DAS-DDI 112 GCN DDI Prediction w/ dual-view framework DrugBank,ChChMiner,ZhangDDI",DDI Prediction w/ dual-view framework,"SSF-DDI 109 MPNN DDI Prediction w/ on sequence and substructure features DrugBank,Twosides",DDI Prediction w/ on sequence and substructure features,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"SSF-DDI 109 MPNN DDI Prediction w/ on sequence and substructure features DrugBank,Twosides",DDI Prediction w/ on sequence and substructure features,"DeepDDS 107 GAT, GCN synergetic DDI Prediction w/ attention mechanism O’Neil’s dataset,Menden’s dataset",synergetic DDI Prediction w/ attention mechanism,1,0,1,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"DeepDDS 107 GAT, GCN synergetic DDI Prediction w/ attention mechanism O’Neil’s dataset,Menden’s dataset",synergetic DDI Prediction w/ attention mechanism,"MD-Syn 111 GCN synergistic DDI Prediction w/ chemicals and cancer cell line gene expression profiles O’Neil’s dataset, DrugCombDB",synergistic DDI Prediction w/ chemicals and cancer cell line gene expression profiles,1,0,1,0,1,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"MD-Syn 111 GCN synergistic DDI Prediction w/ chemicals and cancer cell line gene expression profiles O’Neil’s dataset, DrugCombDB",synergistic DDI Prediction w/ chemicals and cancer cell line gene expression profiles,SafeDrug 40 MPNN Drug Combinations Recommendation w/ explicit leverages of drugs’ molecule structures and model DDIs MIMIC-III,Drug Combinations Recommendation w/ explicit leverages of drugs’ molecule structures and model DDIs,2.7,0,1,1,1,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
SafeDrug 40 MPNN Drug Combinations Recommendation w/ explicit leverages of drugs’ molecule structures and model DDIs MIMIC-III,Drug Combinations Recommendation w/ explicit leverages of drugs’ molecule structures and model DDIs,MoleRec 41 GIN Drug Combinations Recommendation w/ molecular substructure-aware encoding method MIMIC-III,Drug Combinations Recommendation w/ molecular substructure-aware encoding method,1,0,1,1,1,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
MoleRec 41 GIN Drug Combinations Recommendation w/ molecular substructure-aware encoding method MIMIC-III,Drug Combinations Recommendation w/ molecular substructure-aware encoding method,"Carmen 42 GNN Drug Combinations Recommendation w/ context-aware GNN MIMIC-III,MIMIC-IV",Drug Combinations Recommendation w/ context-aware GNN,1,0,1,1,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,5,5,1
"Carmen 42 GNN Drug Combinations Recommendation w/ context-aware GNN MIMIC-III,MIMIC-IV",Drug Combinations Recommendation w/ context-aware GNN,"Graph Isomorphism NetworkGIN, GraphSAGESAGE, Graph Convolutional NetworkGCN, Graph network blockGN blocks","Graph Isomorphism Network(GIN), GraphSAGE(SAGE), Graph Convolutional Network(GCN), Graph network block(GN blocks)",1,-82.91,0,0,0,5.05,5.05,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,5,5,1
"Graph Isomorphism NetworkGIN, GraphSAGESAGE, Graph Convolutional NetworkGCN, Graph network blockGN blocks","Graph Isomorphism Network(GIN), GraphSAGE(SAGE), Graph Convolutional Network(GCN), Graph network block(GN blocks)",and property prediction to the characterization of drug–drug interactions and it serves as a foundation for,and property prediction to the characterization of drug–drug interactions and it serves as a foundation for,15.28,-3.37,1,0,1,5.05,9.96,4.92,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,0
and property prediction to the characterization of drug–drug interactions and it serves as a foundation for,and property prediction to the characterization of drug–drug interactions and it serves as a foundation for,objectively evaluating the effectiveness of various predictive models.,objectively evaluating the effectiveness of various predictive models.,1.84,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
objectively evaluating the effectiveness of various predictive models.,objectively evaluating the effectiveness of various predictive models.,We assembled a comprehensive list of datasets referenced across the reviewed studies and organized,We assembled a comprehensive list of datasets referenced across the reviewed studies and organized,1.84,14.94,0,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,0
"them by their data characteristics, as summarized in Table 2. Four primary categories capture the scope","them by their data characteristics, as summarized in Table 2. Four primary categories capture the scope","of these resources: Comprehensive Databases, Clinical Databases, Structural Information Databases, and","of these resources: Comprehensive Databases, Clinical Databases, Structural Information Databases, and",1,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"of these resources: Comprehensive Databases, Clinical Databases, Structural Information Databases, and","of these resources: Comprehensive Databases, Clinical Databases, Structural Information Databases, and","Molecular Interaction Databases. Given the breadth and interrelated nature of the latter, we subdivided","Molecular Interaction Databases. Given the breadth and interrelated nature of the latter, we subdivided",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"Molecular Interaction Databases. Given the breadth and interrelated nature of the latter, we subdivided","Molecular Interaction Databases. Given the breadth and interrelated nature of the latter, we subdivided","Molecular Interaction Databases into Protein–Ligand Binding and Drug–Drug Interaction collections, each","Molecular Interaction Databases into Protein–Ligand Binding and Drug–Drug Interaction collections, each",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"Molecular Interaction Databases into Protein–Ligand Binding and Drug–Drug Interaction collections, each","Molecular Interaction Databases into Protein–Ligand Binding and Drug–Drug Interaction collections, each","distinguished by color coding in table. While not exhaustive, this selection emphasizes the most influential","distinguished by color coding in table. While not exhaustive, this selection emphasizes the most influential",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"distinguished by color coding in table. While not exhaustive, this selection emphasizes the most influential","distinguished by color coding in table. While not exhaustive, this selection emphasizes the most influential",datasets driving progress in computational drug discovery.,datasets driving progress in computational drug discovery.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
datasets driving progress in computational drug discovery.,datasets driving progress in computational drug discovery.,Table 2: Commonly used benchmark databases and their brief descriptions. Consistent with discussion,Table 2: Commonly used benchmark databases and their brief descriptions. Consistent with discussion,7.2,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,0
Table 2: Commonly used benchmark databases and their brief descriptions. Consistent with discussion,Table 2: Commonly used benchmark databases and their brief descriptions. Consistent with discussion,"in the paper, we separate the datasets into four categories: Comprehensive Databases, Clinical Databases,","in the paper, we separate the datasets into four categories: Comprehensive Databases, Clinical Databases,",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"in the paper, we separate the datasets into four categories: Comprehensive Databases, Clinical Databases,","in the paper, we separate the datasets into four categories: Comprehensive Databases, Clinical Databases,","Structural Information Databases, and Molecular Interaction Databases. The Molecular Interaction category","Structural Information Databases, and Molecular Interaction Databases. The Molecular Interaction category",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"Structural Information Databases, and Molecular Interaction Databases. The Molecular Interaction category","Structural Information Databases, and Molecular Interaction Databases. The Molecular Interaction category",is further divided into Protein–Ligand Binding and Drug–Drug Interaction.,is further divided into Protein–Ligand Binding and Drug–Drug Interaction.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
is further divided into Protein–Ligand Binding and Drug–Drug Interaction.,is further divided into Protein–Ligand Binding and Drug–Drug Interaction.,Task Dataset Description,Description,1.17,125.07,0,0,0,9.96,4.53,-5.43,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,6,6,0
Task Dataset Description,Description,Comprehensive Databases DrugBank 113 Extensive repository of approved and investigational drugs linking chemical structures with pharmacological profiles and target interactions.,Extensive repository of approved and investigational drugs linking chemical structures with pharmacological profiles and target interactions.,1.33,0,1,0,1,4.53,4.53,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,6,6,1
Comprehensive Databases DrugBank 113 Extensive repository of approved and investigational drugs linking chemical structures with pharmacological profiles and target interactions.,Extensive repository of approved and investigational drugs linking chemical structures with pharmacological profiles and target interactions.,PubChem 114 Vast compound library annotated with high-throughput screening bioactivities and comprehensive chemical properties.,Vast compound library annotated with high-throughput screening bioactivities and comprehensive chemical properties.,0.49,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
PubChem 114 Vast compound library annotated with high-throughput screening bioactivities and comprehensive chemical properties.,Vast compound library annotated with high-throughput screening bioactivities and comprehensive chemical properties.,MoleculeNet 21 Aggregated benchmark collection covering diverse molecular properties and activities for algorithm evaluation.,Aggregated benchmark collection covering diverse molecular properties and activities for algorithm evaluation.,0.49,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
MoleculeNet 21 Aggregated benchmark collection covering diverse molecular properties and activities for algorithm evaluation.,Aggregated benchmark collection covering diverse molecular properties and activities for algorithm evaluation.,"Clinical Databases MIMIC-III 115 Detailed, de-identified ICU patient records including vitals, labs, and clinical interventions over time.","Detailed, de-identified ICU patient records including vitals, labs, and clinical interventions over time.",1.32,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
"Clinical Databases MIMIC-III 115 Detailed, de-identified ICU patient records including vitals, labs, and clinical interventions over time.","Detailed, de-identified ICU patient records including vitals, labs, and clinical interventions over time.","MIMIC-IV 116 A public EHR dataset with deidentified clinical data for 180,733 hospital and 50,920 ICU patients, covering patient tracking, billing, medications, and measurements.","A public EHR dataset with deidentified clinical data for 180,733 hospital and 50,920 ICU patients, covering patient tracking, billing, medications, and measurements.",0.49,0,1,1,0,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
"MIMIC-IV 116 A public EHR dataset with deidentified clinical data for 180,733 hospital and 50,920 ICU patients, covering patient tracking, billing, medications, and measurements.","A public EHR dataset with deidentified clinical data for 180,733 hospital and 50,920 ICU patients, covering patient tracking, billing, medications, and measurements.","UK Biobank 117 Population-scale cohort with deep phenotypic, genotypic, and long-term health outcome data.","Population-scale cohort with deep phenotypic, genotypic, and long-term health outcome data.",0.49,0,1,0,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
"UK Biobank 117 Population-scale cohort with deep phenotypic, genotypic, and long-term health outcome data.","Population-scale cohort with deep phenotypic, genotypic, and long-term health outcome data.",Structural Information Databases ZINC 118 Vendor-curated set of purchasable compounds each with experimentally determined 3D conformers.,Vendor-curated set of purchasable compounds each with experimentally determined 3D conformers.,1.32,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
Structural Information Databases ZINC 118 Vendor-curated set of purchasable compounds each with experimentally determined 3D conformers.,Vendor-curated set of purchasable compounds each with experimentally determined 3D conformers.,GEOM 119 High-precision quantum-mechanically optimized 3D molecular geometries for conformational analysis.,High-precision quantum-mechanically optimized 3D molecular geometries for conformational analysis.,0.49,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
GEOM 119 High-precision quantum-mechanically optimized 3D molecular geometries for conformational analysis.,High-precision quantum-mechanically optimized 3D molecular geometries for conformational analysis.,MISATO 120 Multigrained collection of protein–ligand complexes annotated with binding-site details.,Multigrained collection of protein–ligand complexes annotated with binding-site details.,0.49,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
MISATO 120 Multigrained collection of protein–ligand complexes annotated with binding-site details.,Multigrained collection of protein–ligand complexes annotated with binding-site details.,CrossDocked 121 Large-scale docking dataset providing multiple poses and affinity estimates for protein–ligand pairs.,Large-scale docking dataset providing multiple poses and affinity estimates for protein–ligand pairs.,0.49,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
CrossDocked 121 Large-scale docking dataset providing multiple poses and affinity estimates for protein–ligand pairs.,Large-scale docking dataset providing multiple poses and affinity estimates for protein–ligand pairs.,Molecular Interaction Databases ChEMBL 122 Expert-curated database of small molecules linked to experimentally measured target binding affinities.,Expert-curated database of small molecules linked to experimentally measured target binding affinities.,1.32,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
Molecular Interaction Databases ChEMBL 122 Expert-curated database of small molecules linked to experimentally measured target binding affinities.,Expert-curated database of small molecules linked to experimentally measured target binding affinities.,Protein–Ligand Binding Metz Dataset 123 Collection of kinase inhibitor experiments reporting inhibition constants K i  across targets.,Collection of kinase inhibitor experiments reporting inhibition constants (Ki) across targets.,0.49,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
Protein–Ligand Binding Metz Dataset 123 Collection of kinase inhibitor experiments reporting inhibition constants K i  across targets.,Collection of kinase inhibitor experiments reporting inhibition constants (Ki) across targets.,KIBA Dataset 124 Unified resource converting heterogeneous kinase-inhibitor bioactivities into standardized KIBA scores.,Unified resource converting heterogeneous kinase-inhibitor bioactivities into standardized KIBA scores.,0.49,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
KIBA Dataset 124 Unified resource converting heterogeneous kinase-inhibitor bioactivities into standardized KIBA scores.,Unified resource converting heterogeneous kinase-inhibitor bioactivities into standardized KIBA scores.,Davis Dataset 125 Comprehensive mapping of kinase–inhibitor dissociation constants K d  over multiple enzymes.,Comprehensive mapping of kinase–inhibitor dissociation constants (Kd) over multiple enzymes.,0.49,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
Davis Dataset 125 Comprehensive mapping of kinase–inhibitor dissociation constants K d  over multiple enzymes.,Comprehensive mapping of kinase–inhibitor dissociation constants (Kd) over multiple enzymes.,PDBbind Dataset 126 Annotated set of biomolecular complexes with experimentally determined binding affinities and structures.,Annotated set of biomolecular complexes with experimentally determined binding affinities and structures.,0.49,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
PDBbind Dataset 126 Annotated set of biomolecular complexes with experimentally determined binding affinities and structures.,Annotated set of biomolecular complexes with experimentally determined binding affinities and structures.,Molecular Interaction Databases TwoSIDES 127 Pharmacovigilance resource of adverse drug–drug event pairs mined from FAERS reporting data.,Pharmacovigilance resource of adverse drug–drug event pairs mined from FAERS reporting data.,1.32,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
Molecular Interaction Databases TwoSIDES 127 Pharmacovigilance resource of adverse drug–drug event pairs mined from FAERS reporting data.,Pharmacovigilance resource of adverse drug–drug event pairs mined from FAERS reporting data.,Drug–Drug Interaction Deng’s Dataset 128 Multimodal catalog of 570 approved drugs’ interactions stratified by 65 mechanistic event types.,Multimodal catalog of 570 approved drugs’ interactions stratified by 65 mechanistic event types.,0.49,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
Drug–Drug Interaction Deng’s Dataset 128 Multimodal catalog of 570 approved drugs’ interactions stratified by 65 mechanistic event types.,Multimodal catalog of 570 approved drugs’ interactions stratified by 65 mechanistic event types.,"ChChMiner 129 A BioSNAP sub-dataset of 1,514 FDA-approved drugs and 48,514 DDI.","A BioSNAP sub-dataset of 1,514 FDA-approved drugs and 48,514 DDI.",0.49,0,1,1,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
"ChChMiner 129 A BioSNAP sub-dataset of 1,514 FDA-approved drugs and 48,514 DDI.","A BioSNAP sub-dataset of 1,514 FDA-approved drugs and 48,514 DDI.","DrugCombDB 130 Dataset that contains 448,555 combinations of 2,887 drugs across 124 cancer cell lines, labeled as synergistic or antagonistic using multiple scoring models.","Dataset that contains 448,555 combinations of 2,887 drugs across 124 cancer cell lines, labeled as synergistic or antagonistic using multiple scoring models.",0.49,0,1,1,0,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
"DrugCombDB 130 Dataset that contains 448,555 combinations of 2,887 drugs across 124 cancer cell lines, labeled as synergistic or antagonistic using multiple scoring models.","Dataset that contains 448,555 combinations of 2,887 drugs across 124 cancer cell lines, labeled as synergistic or antagonistic using multiple scoring models.","O’Neil’s dataset 131 A dataset that contains 583 drug combinations across 39 cancer cell lines, identifying 287 synergistic and 178 antagonistic pairs among 38 drugs","A dataset that contains 583 drug combinations across 39 cancer cell lines, identifying 287 synergistic and 178 antagonistic pairs among 38 drugs",0.49,0,1,0,0,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,1,6,6,1
"O’Neil’s dataset 131 A dataset that contains 583 drug combinations across 39 cancer cell lines, identifying 287 synergistic and 178 antagonistic pairs among 38 drugs","A dataset that contains 583 drug combinations across 39 cancer cell lines, identifying 287 synergistic and 178 antagonistic pairs among 38 drugs","AstraZeneca’s dataset 31 A dataset that features 910 combinations of 118 drugs across 85 cell lines, with 797 pairs showing high synergy","A dataset that features 910 combinations of 118 drugs across 85 cell lines, with 797 pairs showing high synergy",0.49,0,1,0,1,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,6,6,1
"AstraZeneca’s dataset 31 A dataset that features 910 combinations of 118 drugs across 85 cell lines, with 797 pairs showing high synergy","A dataset that features 910 combinations of 118 drugs across 85 cell lines, with 797 pairs showing high synergy",6.1 Comprehensive Databases,Comprehensive Databases,-40.97,-120.92,0,1,0,4.53,4.53,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,6,6,0
6.1 Comprehensive Databases,Comprehensive Databases,Comprehensive databases are those that contain extensive molecular and biochemical information on drugs,Comprehensive databases are those that contain extensive molecular and biochemical information on drugs,56.76,-4.15,1,0,1,4.53,9.96,5.43,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,6,6,0
Comprehensive databases are those that contain extensive molecular and biochemical information on drugs,Comprehensive databases are those that contain extensive molecular and biochemical information on drugs,"and chemical compounds, including but not limited to compound identifiers, structural representations e.g.,","and chemical compounds, including but not limited to compound identifiers, structural representations (e.g.,",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"and chemical compounds, including but not limited to compound identifiers, structural representations e.g.,","and chemical compounds, including but not limited to compound identifiers, structural representations (e.g.,","SMILES, 2D and/or 3D graphs, indications, and target information. Such data supports a wide range","SMILES, 2D and/or 3D graphs), indications, and target information. Such data supports a wide range",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"SMILES, 2D and/or 3D graphs, indications, and target information. Such data supports a wide range","SMILES, 2D and/or 3D graphs), indications, and target information. Such data supports a wide range",of applications. The compound structure information usually serves as input for computational models,of applications. The compound structure information usually serves as input for computational models,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
of applications. The compound structure information usually serves as input for computational models,of applications. The compound structure information usually serves as input for computational models,"and their labels and properties serve as training data. In this subsection, we include three representative","and their labels and properties serve as training data. In this subsection, we include three representative",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"and their labels and properties serve as training data. In this subsection, we include three representative","and their labels and properties serve as training data. In this subsection, we include three representative","comprehensive databases in drug discovery: DrugBank 113, PubChem 114, and MoleculeNet 21.","comprehensive databases in drug discovery: DrugBank [113], PubChem [114], and MoleculeNet [21].",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"comprehensive databases in drug discovery: DrugBank 113, PubChem 114, and MoleculeNet 21.","comprehensive databases in drug discovery: DrugBank [113], PubChem [114], and MoleculeNet [21].","DrugBank 113 is a comprehensive, freely accessible, online database containing reliable information","DrugBank [113] is a comprehensive, freely accessible, online database containing reliable information",0.96,14.94,0,0,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,6,6,0
"DrugBank 113 is a comprehensive, freely accessible, online database containing reliable information","DrugBank [113] is a comprehensive, freely accessible, online database containing reliable information","on drugs and drug target and is a vital resource for computational drug discovery and pharmaceutical research. The latest release features more than seventeen thousand drug entries, including FDA-approved small","search. The latest release features more than seventeen thousand drug entries, including FDA-approved small",4.94,-14.94,0,0,1,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"on drugs and drug target and is a vital resource for computational drug discovery and pharmaceutical research. The latest release features more than seventeen thousand drug entries, including FDA-approved small","search. The latest release features more than seventeen thousand drug entries, including FDA-approved small","molecule drugs, FDA-approved biotech protein/peptide drugs, nutraceuticals, and experimental drugs. For","molecule drugs, FDA-approved biotech (protein/peptide) drugs, nutraceuticals, and experimental drugs. For",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"molecule drugs, FDA-approved biotech protein/peptide drugs, nutraceuticals, and experimental drugs. For","molecule drugs, FDA-approved biotech (protein/peptide) drugs, nutraceuticals, and experimental drugs. For","each drug entry, DrugBank contains chemical, pharmacological, and pharmaceutical properties of the drug","each drug entry, DrugBank contains chemical, pharmacological, and pharmaceutical properties of the drug",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"each drug entry, DrugBank contains chemical, pharmacological, and pharmaceutical properties of the drug","each drug entry, DrugBank contains chemical, pharmacological, and pharmaceutical properties of the drug","as well as links to external databases. In addition, DrugBank also provide sequence, structure, and pathway","as well as links to external databases. In addition, DrugBank also provide sequence, structure, and pathway",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"as well as links to external databases. In addition, DrugBank also provide sequence, structure, and pathway","as well as links to external databases. In addition, DrugBank also provide sequence, structure, and pathway","information of around six thousand unique proteins, which are drug targets/enzymes/transporters/carriers","information of around six thousand unique proteins, which are drug targets/enzymes/transporters/carriers",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"information of around six thousand unique proteins, which are drug targets/enzymes/transporters/carriers","information of around six thousand unique proteins, which are drug targets/enzymes/transporters/carriers","associated with these drugs. The information about drug structures, indications, drug-target interactions,","associated with these drugs. The information about drug structures, indications, drug-target interactions,",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"associated with these drugs. The information about drug structures, indications, drug-target interactions,","associated with these drugs. The information about drug structures, indications, drug-target interactions,","and pathways can support a wide range of tasks such as drug property prediction, drug activity analysis,","and pathways can support a wide range of tasks such as drug property prediction, drug activity analysis,",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"and pathways can support a wide range of tasks such as drug property prediction, drug activity analysis,","and pathways can support a wide range of tasks such as drug property prediction, drug activity analysis,","drug repurposing, and drug-target interaction prediction.","drug repurposing, and drug-target interaction prediction.",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"drug repurposing, and drug-target interaction prediction.","drug repurposing, and drug-target interaction prediction.","PubChem 114 is another comprehensive database of chemical molecules and their activities against biological assays, which is maintained by the National Center for Biotechnology Information NCBI. It serves","ological assays, which is maintained by the National Center for Biotechnology Information (NCBI). It serves",4.92,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,0
"PubChem 114 is another comprehensive database of chemical molecules and their activities against biological assays, which is maintained by the National Center for Biotechnology Information NCBI. It serves","ological assays, which is maintained by the National Center for Biotechnology Information (NCBI). It serves","as a comprehensive resource for information on the chemical structures, properties, biological activities, and","as a comprehensive resource for information on the chemical structures, properties, biological activities, and",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"toxicity of small molecules, and is widely used in cheminformatics, bioinformatics, and computational drug","toxicity of small molecules, and is widely used in cheminformatics, bioinformatics, and computational drug","discovery. PubChem is organized into three main interlinked databases: PubChem Compound, PubChem","discovery. PubChem is organized into three main interlinked databases: PubChem Compound, PubChem",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"discovery. PubChem is organized into three main interlinked databases: PubChem Compound, PubChem","discovery. PubChem is organized into three main interlinked databases: PubChem Compound, PubChem","Substance, and PubChem BioAssay PCBA. PubChem Compound database contains information of more","Substance, and PubChem BioAssay (PCBA). PubChem Compound database contains information of more",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,7,7,1
"Substance, and PubChem BioAssay PCBA. PubChem Compound database contains information of more","Substance, and PubChem BioAssay (PCBA). PubChem Compound database contains information of more",than 100 million pure and characterized chemical compounds. The Substance section collects information of,than 100 million pure and characterized chemical compounds. The Substance section collects information of,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
than 100 million pure and characterized chemical compounds. The Substance section collects information of,than 100 million pure and characterized chemical compounds. The Substance section collects information of,"substances, including mixtures and uncharacterized substances, submitted by various data contributors. The","substances, including mixtures and uncharacterized substances, submitted by various data contributors. The",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"substances, including mixtures and uncharacterized substances, submitted by various data contributors. The","substances, including mixtures and uncharacterized substances, submitted by various data contributors. The",BioAssay section contains bioactivity results from approximately 1.67 million biological assay experiments.,BioAssay section contains bioactivity results from approximately 1.67 million biological assay experiments.,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,7,7,1
BioAssay section contains bioactivity results from approximately 1.67 million biological assay experiments.,BioAssay section contains bioactivity results from approximately 1.67 million biological assay experiments.,PubChem Compound IDs are widely used across chemical databases for consistent referencing.,PubChem Compound IDs are widely used across chemical databases for consistent referencing.,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,7,7,1
PubChem Compound IDs are widely used across chemical databases for consistent referencing.,PubChem Compound IDs are widely used across chemical databases for consistent referencing.,MoleculeNet 21 is a benchmarking platform designed to facilitate the development and evaluation of,MoleculeNet [21] is a benchmarking platform designed to facilitate the development and evaluation of,0.96,14.94,0,1,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,7,7,0
MoleculeNet 21 is a benchmarking platform designed to facilitate the development and evaluation of,MoleculeNet [21] is a benchmarking platform designed to facilitate the development and evaluation of,machine learning models for molecular property prediction. The authors curated a wide variety of datasets,machine learning models for molecular property prediction. The authors curated a wide variety of datasets,1.02,-14.94,0,0,1,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
machine learning models for molecular property prediction. The authors curated a wide variety of datasets,machine learning models for molecular property prediction. The authors curated a wide variety of datasets,"from other primary sources, covering different molecular properties and tasks. Although it is not as complex as the two database mentioned earlier, it had been utilized frequently in evaluating newly proposed","plex as the two database mentioned earlier, it had been utilized frequently in evaluating newly proposed",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"from other primary sources, covering different molecular properties and tasks. Although it is not as complex as the two database mentioned earlier, it had been utilized frequently in evaluating newly proposed","plex as the two database mentioned earlier, it had been utilized frequently in evaluating newly proposed",machine learning approaches because the datasets were constructed for specific tasks and were organized in,machine learning approaches because the datasets were constructed for specific tasks and were organized in,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
machine learning approaches because the datasets were constructed for specific tasks and were organized in,machine learning approaches because the datasets were constructed for specific tasks and were organized in,"a very simple format for download. Briefly, the datasets cover four different types of properties, including","a very simple format for download. Briefly, the datasets cover four different types of properties, including",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"a very simple format for download. Briefly, the datasets cover four different types of properties, including","a very simple format for download. Briefly, the datasets cover four different types of properties, including","Quantum Mechanics including datasets QM7, QM8, QM9, Physical Chemistry datasets ESOL, FreeSolv,","Quantum Mechanics (including datasets QM7, QM8, QM9), Physical Chemistry (datasets ESOL, FreeSolv,",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,7,7,1
"Quantum Mechanics including datasets QM7, QM8, QM9, Physical Chemistry datasets ESOL, FreeSolv,","Quantum Mechanics (including datasets QM7, QM8, QM9), Physical Chemistry (datasets ESOL, FreeSolv,","Lipophilicity, Biophysics datasets PCBA, MUV, HIV, BACE, and Physiology datasets BBBP, Tox21,","Lipophilicity), Biophysics (datasets PCBA, MUV, HIV, BACE), and Physiology (datasets BBBP, Tox21,",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,7,7,1
"Lipophilicity, Biophysics datasets PCBA, MUV, HIV, BACE, and Physiology datasets BBBP, Tox21,","Lipophilicity), Biophysics (datasets PCBA, MUV, HIV, BACE), and Physiology (datasets BBBP, Tox21,","SIDER, ClinTox. The prediction tasks can be either classification or regression. As a reference, we provide","SIDER, ClinTox). The prediction tasks can be either classification or regression. As a reference, we provide",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,7,7,1
"SIDER, ClinTox. The prediction tasks can be either classification or regression. As a reference, we provide","SIDER, ClinTox). The prediction tasks can be either classification or regression. As a reference, we provide",a very brief summary for each of the datasets.,a very brief summary for each of the datasets.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
a very brief summary for each of the datasets.,a very brief summary for each of the datasets.,"QM7, QM8, QM9 provide quantum mechanical properties and 3D molecular geometries that can be","QM7, QM8, QM9 provide quantum mechanical properties and 3D molecular geometries that can be",0.96,14.94,0,0,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,7,7,0
"QM7, QM8, QM9 provide quantum mechanical properties and 3D molecular geometries that can be","QM7, QM8, QM9 provide quantum mechanical properties and 3D molecular geometries that can be","used as training data for quantum property prediction. QM7 includes 7,165 molecules computed atomization","used as training data for quantum property prediction. QM7 includes 7,165 molecules computed atomization",1.02,-14.94,0,0,1,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"used as training data for quantum property prediction. QM7 includes 7,165 molecules computed atomization","used as training data for quantum property prediction. QM7 includes 7,165 molecules computed atomization","energies and Coulomb matrices. QM8 includes 21,786 molecules with calculated electronic spectra. QM9","energies and Coulomb matrices. QM8 includes 21,786 molecules with calculated electronic spectra. QM9",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"energies and Coulomb matrices. QM8 includes 21,786 molecules with calculated electronic spectra. QM9","energies and Coulomb matrices. QM8 includes 21,786 molecules with calculated electronic spectra. QM9","expands to over 133,000 stable organic compounds with detailed quantum mechanical properties including","expands to over 133,000 stable organic compounds with detailed quantum mechanical properties including",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"expands to over 133,000 stable organic compounds with detailed quantum mechanical properties including","expands to over 133,000 stable organic compounds with detailed quantum mechanical properties including","energies, geometries, and vibrational frequencies.","energies, geometries, and vibrational frequencies.",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"energies, geometries, and vibrational frequencies.","energies, geometries, and vibrational frequencies.","ESOL is small dataset of 1,128 molecules in SMILES format offering water solubility data, useful","ESOL is small dataset of 1,128 molecules in SMILES format offering water solubility data, useful",0.96,14.94,0,0,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,7,7,0
"ESOL is small dataset of 1,128 molecules in SMILES format offering water solubility data, useful","ESOL is small dataset of 1,128 molecules in SMILES format offering water solubility data, useful",for evaluating solubility predictions. FreeSolv contains 642 small molecules with both experimental and,for evaluating solubility predictions. FreeSolv contains 642 small molecules with both experimental and,1.02,-14.94,0,0,0,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
for evaluating solubility predictions. FreeSolv contains 642 small molecules with both experimental and,for evaluating solubility predictions. FreeSolv contains 642 small molecules with both experimental and,computed hydration free energies. Lipophilicity reports log D values of the octanol–water distribution,computed hydration free energies. Lipophilicity reports log D values of the octanol–water distribution,1,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
computed hydration free energies. Lipophilicity reports log D values of the octanol–water distribution,computed hydration free energies. Lipophilicity reports log D values of the octanol–water distribution,"coefficients for over 4,200 drug molecules, reflecting membrane permeability and solubility.","coefficients for over 4,200 drug molecules, reflecting membrane permeability and solubility.",1,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"coefficients for over 4,200 drug molecules, reflecting membrane permeability and solubility.","coefficients for over 4,200 drug molecules, reflecting membrane permeability and solubility.","PCBA contains activity profiles for over 400,000 molecules against specific enzymes, receptors, and","PCBA contains activity profiles for over 400,000 molecules against specific enzymes, receptors, and",0.96,14.94,0,1,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,7,7,0
"PCBA contains activity profiles for over 400,000 molecules against specific enzymes, receptors, and","PCBA contains activity profiles for over 400,000 molecules against specific enzymes, receptors, and","pathways, derived from PubChem BioAssay database. MUV is a filtered subset of PubChem BioAssay,","pathways, derived from PubChem BioAssay database. MUV is a filtered subset of PubChem BioAssay,",1.02,-14.94,0,0,0,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"pathways, derived from PubChem BioAssay database. MUV is a filtered subset of PubChem BioAssay,","pathways, derived from PubChem BioAssay database. MUV is a filtered subset of PubChem BioAssay,",designed to validate virtual screening techniques and includes 17 benchmark tasks. HIV contains more than,designed to validate virtual screening techniques and includes 17 benchmark tasks. HIV contains more than,1,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
designed to validate virtual screening techniques and includes 17 benchmark tasks. HIV contains more than,designed to validate virtual screening techniques and includes 17 benchmark tasks. HIV contains more than,41 thousand molecules labeled for their ability to inhibit HIV replication based on biological assay data.,41 thousand molecules labeled for their ability to inhibit HIV replication based on biological assay data.,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,7,7,1
41 thousand molecules labeled for their ability to inhibit HIV replication based on biological assay data.,41 thousand molecules labeled for their ability to inhibit HIV replication based on biological assay data.,"BACE includes 1,513 inhibitors of human ß -secretase 1 BACE-1, with both binary activity labels and","BACE includes 1,513 inhibitors of human ß-secretase 1 (BACE-1), with both binary activity labels and",0.96,0,1,1,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,7,7,1
"BACE includes 1,513 inhibitors of human ß -secretase 1 BACE-1, with both binary activity labels and","BACE includes 1,513 inhibitors of human ß-secretase 1 (BACE-1), with both binary activity labels and",IC50 values.,IC50 values.,1.02,0,1,0,0,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,7,7,1
IC50 values.,IC50 values.,"BBBP includes more than two thousand molecules labeled based on whether they can cross the bloodbrain barrier. Tox21 contains toxicity data for close to eight thousand compounds across 12 targets, used in","brain barrier. Tox21 contains toxicity data for close to eight thousand compounds across 12 targets, used in",4.92,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,7,7,0
"BBBP includes more than two thousand molecules labeled based on whether they can cross the bloodbrain barrier. Tox21 contains toxicity data for close to eight thousand compounds across 12 targets, used in","brain barrier. Tox21 contains toxicity data for close to eight thousand compounds across 12 targets, used in","toxicology modeling. ToxCast extends Tox21, with bioactivity measurements on 617 biological targets for","toxicology modeling. ToxCast extends Tox21, with bioactivity measurements on 617 biological targets for",1,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"toxicology modeling. ToxCast extends Tox21, with bioactivity measurements on 617 biological targets for","toxicology modeling. ToxCast extends Tox21, with bioactivity measurements on 617 biological targets for","8,576 compounds. SIDER focuses on close to fifteen hundred marketed drugs and their recorded adverse","8,576 compounds. SIDER focuses on close to fifteen hundred marketed drugs and their recorded adverse",1,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,7,7,1
"8,576 compounds. SIDER focuses on close to fifteen hundred marketed drugs and their recorded adverse","8,576 compounds. SIDER focuses on close to fifteen hundred marketed drugs and their recorded adverse",drug reactions more than five thousand side effects. ClinTox contains approved drugs and compounds that,drug reactions (more than five thousand side effects). ClinTox contains approved drugs and compounds that,1,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
drug reactions more than five thousand side effects. ClinTox contains approved drugs and compounds that,drug reactions (more than five thousand side effects). ClinTox contains approved drugs and compounds that,failed clinical trials due to toxicity concerns.,failed clinical trials due to toxicity concerns.,1,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
failed clinical trials due to toxicity concerns.,failed clinical trials due to toxicity concerns.,"Each dataset is accompanied by task definitions e.g., classification or regression, standard metrics","Each dataset is accompanied by task definitions (e.g., classification or regression), standard metrics",1,14.94,0,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,7,7,0
"Each dataset is accompanied by task definitions e.g., classification or regression, standard metrics","Each dataset is accompanied by task definitions (e.g., classification or regression), standard metrics","e.g., ROC-AUC, RMSE, and data preprocessing techniques e.g., scaffold splits, random splits to promote","(e.g., ROC-AUC, RMSE), and data preprocessing techniques (e.g., scaffold splits, random splits) to promote",1,-14.94,0,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"e.g., ROC-AUC, RMSE, and data preprocessing techniques e.g., scaffold splits, random splits to promote","(e.g., ROC-AUC, RMSE), and data preprocessing techniques (e.g., scaffold splits, random splits) to promote",consistent model evaluation.,consistent model evaluation.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
consistent model evaluation.,consistent model evaluation.,6.2 Clinical Databases,Clinical Databases,5.94,26.9,0,0,0,9.96,11.96,1.99,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,7,7,0
6.2 Clinical Databases,Clinical Databases,Clinical databases are those databases that contain clinical and health information from patients that can,Clinical databases are those databases that contain clinical and health information from patients that can,3.09,-26.9,0,0,1,11.96,9.96,-1.99,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,7,7,0
Clinical databases are those databases that contain clinical and health information from patients that can,Clinical databases are those databases that contain clinical and health information from patients that can,"be used for disease prediction, treatment outcome modeling, as well as drug recommendation and preci","be used for disease prediction, treatment outcome modeling, as well as drug recommendation and preci-",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
sion medicine. We therefore list two popular databases here: Medical Information Mart for Intensive Care,sion medicine. We therefore list two popular databases here: Medical Information Mart for Intensive Care,"database MIMIC-III 115 and MIMIC-IV 116, and the UK Biobank database 117.","database (MIMIC-III [115] and MIMIC-IV [116]), and the UK Biobank database [117].",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"database MIMIC-III 115 and MIMIC-IV 116, and the UK Biobank database 117.","database (MIMIC-III [115] and MIMIC-IV [116]), and the UK Biobank database [117].","MIMIC-III 115 and MIMIC-IV 116 are freely accessible, large-scale clinical databases developed","MIMIC-III [115] and MIMIC-IV [116] are freely accessible, large-scale clinical databases developed",0.96,14.94,0,0,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,8,8,0
"MIMIC-III 115 and MIMIC-IV 116 are freely accessible, large-scale clinical databases developed","MIMIC-III [115] and MIMIC-IV [116] are freely accessible, large-scale clinical databases developed",by the MIT Lab for Computational Physiology. While MIMIC-IV is an updated and improved version of,by the MIT Lab for Computational Physiology. While MIMIC-IV is an updated and improved version of,1.02,-14.94,0,0,1,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
by the MIT Lab for Computational Physiology. While MIMIC-IV is an updated and improved version of,by the MIT Lab for Computational Physiology. While MIMIC-IV is an updated and improved version of,"MIMIC-III, and there are overlapped samples in the two database, MIMIC-IV does not encompass all the","MIMIC-III, and there are overlapped samples in the two database, MIMIC-IV does not encompass all the",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,8,8,1
"MIMIC-III, and there are overlapped samples in the two database, MIMIC-IV does not encompass all the","MIMIC-III, and there are overlapped samples in the two database, MIMIC-IV does not encompass all the","data present in MIMIC-III. We briefly discuss both databases. MIMIC-III contains de-identified healthrelated data associated with over 40,000 patients who stayed in critical care units of the Beth Israel Deaconess Medical Center BIDMC between 2001 and 2012. The database includes a wide range of data types",coness Medical Center (BIDMC) between 2001 and 2012. The database includes a wide range of data types,8.84,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"data present in MIMIC-III. We briefly discuss both databases. MIMIC-III contains de-identified healthrelated data associated with over 40,000 patients who stayed in critical care units of the Beth Israel Deaconess Medical Center BIDMC between 2001 and 2012. The database includes a wide range of data types",coness Medical Center (BIDMC) between 2001 and 2012. The database includes a wide range of data types,"across 26 tables, such as demographics, vital signs, laboratory test results, medications, diagnostic codes","across 26 tables, such as demographics, vital signs, laboratory test results, medications, diagnostic codes",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"across 26 tables, such as demographics, vital signs, laboratory test results, medications, diagnostic codes","across 26 tables, such as demographics, vital signs, laboratory test results, medications, diagnostic codes","ICD-9, procedures, imaging reports, and clinical notes. Its structured and time-stamped data makes it especially valuable for developing and validating models for disease risk and patient trajectory prediction. In",pecially valuable for developing and validating models for disease risk and patient trajectory prediction. In,4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,8,8,1
"ICD-9, procedures, imaging reports, and clinical notes. Its structured and time-stamped data makes it especially valuable for developing and validating models for disease risk and patient trajectory prediction. In",pecially valuable for developing and validating models for disease risk and patient trajectory prediction. In,"addition, the dataset has also been frequently employed in studies on drug recommendations and drug combination recommendations after extensive preprocessing. On the other hand MIMIC-IV includes detailed,","bination recommendations after extensive preprocessing. On the other hand MIMIC-IV includes detailed,",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"addition, the dataset has also been frequently employed in studies on drug recommendations and drug combination recommendations after extensive preprocessing. On the other hand MIMIC-IV includes detailed,","bination recommendations after extensive preprocessing. On the other hand MIMIC-IV includes detailed,","de-identified clinical data for 180,733 patients for hospital admissions and 50,920 patients for ICU admissions from BIDMC between 2008 and 2019. Information available includes patient measurements, orders,","sions from BIDMC between 2008 and 2019. Information available includes patient measurements, orders,",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"de-identified clinical data for 180,733 patients for hospital admissions and 50,920 patients for ICU admissions from BIDMC between 2008 and 2019. Information available includes patient measurements, orders,","sions from BIDMC between 2008 and 2019. Information available includes patient measurements, orders,","diagnoses, procedures, treatments, and de-identified free-text clinical notes. Both datasets support a wide","diagnoses, procedures, treatments, and de-identified free-text clinical notes. Both datasets support a wide",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"diagnoses, procedures, treatments, and de-identified free-text clinical notes. Both datasets support a wide","diagnoses, procedures, treatments, and de-identified free-text clinical notes. Both datasets support a wide",array of research studies and help to reduce barriers to conducting clinical research using patient level data.,array of research studies and help to reduce barriers to conducting clinical research using patient level data.,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
array of research studies and help to reduce barriers to conducting clinical research using patient level data.,array of research studies and help to reduce barriers to conducting clinical research using patient level data.,UK Biobank 117 is another large-scale biomedical database and research resource containing in-depth,UK Biobank [117] is another large-scale biomedical database and research resource containing in-depth,0.96,14.94,0,1,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,8,8,0
UK Biobank 117 is another large-scale biomedical database and research resource containing in-depth,UK Biobank [117] is another large-scale biomedical database and research resource containing in-depth,"genetic, lifestyle, and health information from approximately 500,000 volunteer participants aged 40–69 at","genetic, lifestyle, and health information from approximately 500,000 volunteer participants aged 40–69 at",1.02,-14.94,0,0,1,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"genetic, lifestyle, and health information from approximately 500,000 volunteer participants aged 40–69 at","genetic, lifestyle, and health information from approximately 500,000 volunteer participants aged 40–69 at",the time of recruitment 2006–2010 across the United Kingdom. It is managed by a charitable organization and made available to approved researchers for health-related research. The dataset includes a broad,tion and made available to approved researchers for health-related research. The dataset includes a broad,4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
the time of recruitment 2006–2010 across the United Kingdom. It is managed by a charitable organization and made available to approved researchers for health-related research. The dataset includes a broad,tion and made available to approved researchers for health-related research. The dataset includes a broad,"array of data types, such as genotyping and whole-genome sequencing, biochemical assays, physical measures, imaging data e.g., MRI, CT scans, hospital and primary care records, and detailed lifestyle and","sures, imaging data (e.g., MRI, CT scans), hospital and primary care records, and detailed lifestyle and",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"array of data types, such as genotyping and whole-genome sequencing, biochemical assays, physical measures, imaging data e.g., MRI, CT scans, hospital and primary care records, and detailed lifestyle and","sures, imaging data (e.g., MRI, CT scans), hospital and primary care records, and detailed lifestyle and",demographic questionnaires. UK Biobank is particularly valuable for population-level studies on complex,demographic questionnaires. UK Biobank is particularly valuable for population-level studies on complex,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
demographic questionnaires. UK Biobank is particularly valuable for population-level studies on complex,demographic questionnaires. UK Biobank is particularly valuable for population-level studies on complex,diseases. The integration of genetic with phenotypic and clinical data makes it one of the most important,diseases. The integration of genetic with phenotypic and clinical data makes it one of the most important,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
diseases. The integration of genetic with phenotypic and clinical data makes it one of the most important,diseases. The integration of genetic with phenotypic and clinical data makes it one of the most important,"resources for identifying drug targets, predicting drug effects, and accelerating drug development.","resources for identifying drug targets, predicting drug effects, and accelerating drug development.",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"resources for identifying drug targets, predicting drug effects, and accelerating drug development.","resources for identifying drug targets, predicting drug effects, and accelerating drug development.",6.3 Structural Information Databases,Structural Information Databases,5.94,26.9,0,1,0,9.96,11.96,1.99,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,8,8,0
6.3 Structural Information Databases,Structural Information Databases,Structural information datasets focus on providing 3D structures and/or conformers of isolated ligand and/or,Structural information datasets focus on providing 3D structures and/or conformers of isolated ligand and/or,3.09,-26.9,0,0,1,11.96,9.96,-1.99,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,8,8,0
Structural information datasets focus on providing 3D structures and/or conformers of isolated ligand and/or,Structural information datasets focus on providing 3D structures and/or conformers of isolated ligand and/or,protein–ligand complexes. These resources combine experimental structures with computationally refined,protein–ligand complexes. These resources combine experimental structures with computationally refined,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
protein–ligand complexes. These resources combine experimental structures with computationally refined,protein–ligand complexes. These resources combine experimental structures with computationally refined,conformations to support a range of applications – from physics-based simulations such as free energy calculations to data-driven machine learning models that predict binding affinity or molecular properties. In this,culations to data-driven machine learning models that predict binding affinity or molecular properties. In this,4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
conformations to support a range of applications – from physics-based simulations such as free energy calculations to data-driven machine learning models that predict binding affinity or molecular properties. In this,culations to data-driven machine learning models that predict binding affinity or molecular properties. In this,"subsection, we highlight four widely used structural datasets: ZINC 118, GEOM 119, MISATO 84,","subsection, we highlight four widely used structural datasets: ZINC [118], GEOM [119], MISATO [84],",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"subsection, we highlight four widely used structural datasets: ZINC 118, GEOM 119, MISATO 84,","subsection, we highlight four widely used structural datasets: ZINC [118], GEOM [119], MISATO [84],",and CrossDocked 121.,and CrossDocked [121].,1,0,1,0,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
and CrossDocked 121.,and CrossDocked [121].,ZINC 118 is a meticulously curated repository containing over 230 million commercially accessible,ZINC [118] is a meticulously curated repository containing over 230 million commercially accessible,0.96,14.94,0,0,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,8,8,0
ZINC 118 is a meticulously curated repository containing over 230 million commercially accessible,ZINC [118] is a meticulously curated repository containing over 230 million commercially accessible,"compounds. It includes 3D structures, physicochemical properties, and vendor metadata. Unlike theoretical libraries, ZINC focuses on experimentally testable molecules, facilitating streamlined drug discovery","ical libraries, ZINC focuses on experimentally testable molecules, facilitating streamlined drug discovery",4.94,-14.94,0,0,1,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"compounds. It includes 3D structures, physicochemical properties, and vendor metadata. Unlike theoretical libraries, ZINC focuses on experimentally testable molecules, facilitating streamlined drug discovery","ical libraries, ZINC focuses on experimentally testable molecules, facilitating streamlined drug discovery","workflows. The database provides SMILES strings, 3D structures, and drug-like property classifications,","workflows. The database provides SMILES strings, 3D structures, and drug-like property classifications,",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"workflows. The database provides SMILES strings, 3D structures, and drug-like property classifications,","workflows. The database provides SMILES strings, 3D structures, and drug-like property classifications,",organized into tranches for targeted virtual screening. As a benchmark for docking and virtual screening,organized into tranches for targeted virtual screening. As a benchmark for docking and virtual screening,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
organized into tranches for targeted virtual screening. As a benchmark for docking and virtual screening,organized into tranches for targeted virtual screening. As a benchmark for docking and virtual screening,"studies, ZINC accelerates the transition from computational predictions to experimental validation, serving","studies, ZINC accelerates the transition from computational predictions to experimental validation, serving",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"studies, ZINC accelerates the transition from computational predictions to experimental validation, serving","studies, ZINC accelerates the transition from computational predictions to experimental validation, serving",as a critical tool for hit identification and lead optimization.,as a critical tool for hit identification and lead optimization.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
as a critical tool for hit identification and lead optimization.,as a critical tool for hit identification and lead optimization.,"GEOM 119 contains quantum mechanics-optimized 3D geometries for approximately 30 million conformers representing 450,000 drug-like molecules. Each structure is refined using density functional theory DFT to capture realistic conformational landscapes, emphasizing ensembles of energetically feasible","ory (DFT) to capture realistic conformational landscapes, emphasizing ensembles of energetically feasible",8.84,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,8,8,0
"GEOM 119 contains quantum mechanics-optimized 3D geometries for approximately 30 million conformers representing 450,000 drug-like molecules. Each structure is refined using density functional theory DFT to capture realistic conformational landscapes, emphasizing ensembles of energetically feasible","ory (DFT) to capture realistic conformational landscapes, emphasizing ensembles of energetically feasible","states rather than static geometries. This ensemble approach advances protein-ligand interaction modeling,","states rather than static geometries. This ensemble approach advances protein-ligand interaction modeling,",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,8,8,1
"conformer generation algorithms, and force field validation. Its high accuracy has substantially advanced","conformer generation algorithms, and force field validation. Its high accuracy has substantially advanced",3D-aware machine learning models for molecular property prediction and molecule generation.,3D-aware machine learning models for molecular property prediction and molecule generation.,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,9,9,1
3D-aware machine learning models for molecular property prediction and molecule generation.,3D-aware machine learning models for molecular property prediction and molecule generation.,"MISATO 84 is a machine learning-oriented dataset comprising roughly 20,000 experimentally resolved protein–ligand complexes. Each complex undergoes structural refinement and quantum-mechanical",solved protein–ligand complexes. Each complex undergoes structural refinement and quantum-mechanical,4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,9,9,0
"MISATO 84 is a machine learning-oriented dataset comprising roughly 20,000 experimentally resolved protein–ligand complexes. Each complex undergoes structural refinement and quantum-mechanical",solved protein–ligand complexes. Each complex undergoes structural refinement and quantum-mechanical,"optimization to address stereochemical, geometric, and protonation inconsistencies. Around 17,000 complexes are further subjected to explicit-solvent molecular dynamics MD simulations. This dynamic data",plexes are further subjected to explicit-solvent molecular dynamics (MD) simulations. This dynamic data,4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"optimization to address stereochemical, geometric, and protonation inconsistencies. Around 17,000 complexes are further subjected to explicit-solvent molecular dynamics MD simulations. This dynamic data",plexes are further subjected to explicit-solvent molecular dynamics (MD) simulations. This dynamic data,"captures conformational flexibility and binding pocket dynamics. In addition, MISATO includes quantumderived electronic descriptors, partial charges, and preprocessing utilities tailored for machine learning","derived electronic descriptors, partial charges, and preprocessing utilities tailored for machine learning",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"captures conformational flexibility and binding pocket dynamics. In addition, MISATO includes quantumderived electronic descriptors, partial charges, and preprocessing utilities tailored for machine learning","derived electronic descriptors, partial charges, and preprocessing utilities tailored for machine learning","pipelines. By integrating static structures with time-resolved dynamics, MISATO enables modeling of transient binding states and induced-fit effects, overcoming the limitations of single-conformation datasets.","sient binding states and induced-fit effects, overcoming the limitations of single-conformation datasets.",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"pipelines. By integrating static structures with time-resolved dynamics, MISATO enables modeling of transient binding states and induced-fit effects, overcoming the limitations of single-conformation datasets.","sient binding states and induced-fit effects, overcoming the limitations of single-conformation datasets.","CrossDocked 121 curates 18,450 non-redundant protein–ligand complexes derived from the Protein","CrossDocked [121] curates 18,450 non-redundant protein–ligand complexes derived from the Protein",0.96,14.94,0,1,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,9,9,0
"CrossDocked 121 curates 18,450 non-redundant protein–ligand complexes derived from the Protein","CrossDocked [121] curates 18,450 non-redundant protein–ligand complexes derived from the Protein","Data Bank PDB 132, using a systematic cross-docking approach. Ligands are docked into non-cognate,","Data Bank (PDB) [132], using a systematic cross-docking approach. Ligands are docked into non-cognate,",1.02,-14.94,0,0,0,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,9,9,1
"Data Bank PDB 132, using a systematic cross-docking approach. Ligands are docked into non-cognate,","Data Bank (PDB) [132], using a systematic cross-docking approach. Ligands are docked into non-cognate,",structurally similar binding pockets to produce a diverse set of over 22.5 million binding poses. The dataset,structurally similar binding pockets to produce a diverse set of over 22.5 million binding poses. The dataset,1,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
structurally similar binding pockets to produce a diverse set of over 22.5 million binding poses. The dataset,structurally similar binding pockets to produce a diverse set of over 22.5 million binding poses. The dataset,features cluster-based predefined splits for evaluating model generalizability to unseen targets and provides,features cluster-based predefined splits for evaluating model generalizability to unseen targets and provides,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
features cluster-based predefined splits for evaluating model generalizability to unseen targets and provides,features cluster-based predefined splits for evaluating model generalizability to unseen targets and provides,dual metrics for assessing both pose accuracy and binding affinity predictions. By modulating the structural,dual metrics for assessing both pose accuracy and binding affinity predictions. By modulating the structural,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
dual metrics for assessing both pose accuracy and binding affinity predictions. By modulating the structural,dual metrics for assessing both pose accuracy and binding affinity predictions. By modulating the structural,"similarity between docking receptors and their native counterparts, CrossDocked enables rigorous evaluation","similarity between docking receptors and their native counterparts, CrossDocked enables rigorous evaluation",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"similarity between docking receptors and their native counterparts, CrossDocked enables rigorous evaluation","similarity between docking receptors and their native counterparts, CrossDocked enables rigorous evaluation",of docking algorithms under realistic scenarios where exact receptor structures may be unknown. Designed,of docking algorithms under realistic scenarios where exact receptor structures may be unknown. Designed,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
of docking algorithms under realistic scenarios where exact receptor structures may be unknown. Designed,of docking algorithms under realistic scenarios where exact receptor structures may be unknown. Designed,"as a comprehensive benchmark, CrossDocked supports the standardized training and evaluation of 3D CNNs","as a comprehensive benchmark, CrossDocked supports the standardized training and evaluation of 3D CNNs",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"as a comprehensive benchmark, CrossDocked supports the standardized training and evaluation of 3D CNNs","as a comprehensive benchmark, CrossDocked supports the standardized training and evaluation of 3D CNNs","and other ML models for non-native protein–ligand interaction modeling, with broad implications for virtual","and other ML models for non-native protein–ligand interaction modeling, with broad implications for virtual",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"and other ML models for non-native protein–ligand interaction modeling, with broad implications for virtual","and other ML models for non-native protein–ligand interaction modeling, with broad implications for virtual",screening.,screening.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
screening.,screening.,6.4 Molecular Interaction Databases,Molecular Interaction Databases,5.94,26.9,0,0,0,9.96,11.96,1.99,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,9,9,0
6.4 Molecular Interaction Databases,Molecular Interaction Databases,Molecular interactions databases record relationships among different molecules in various formats and are,Molecular interactions databases record relationships among different molecules in various formats and are,3.09,-26.9,0,0,1,11.96,9.96,-1.99,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,9,9,0
Molecular interactions databases record relationships among different molecules in various formats and are,Molecular interactions databases record relationships among different molecules in various formats and are,"fundamental in the study of molecular biology, computational chemistry, and drug discovery. Researchers","fundamental in the study of molecular biology, computational chemistry, and drug discovery. Researchers",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"fundamental in the study of molecular biology, computational chemistry, and drug discovery. Researchers","fundamental in the study of molecular biology, computational chemistry, and drug discovery. Researchers","use these datasets to elucidate biochemical pathways, predict binding affinities, evaluate selectivity, and","use these datasets to elucidate biochemical pathways, predict binding affinities, evaluate selectivity, and",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"use these datasets to elucidate biochemical pathways, predict binding affinities, evaluate selectivity, and","use these datasets to elucidate biochemical pathways, predict binding affinities, evaluate selectivity, and","simulate off-target effects. We include datasets that capture a range of molecular interactions, grouped into","simulate off-target effects. We include datasets that capture a range of molecular interactions, grouped into",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"simulate off-target effects. We include datasets that capture a range of molecular interactions, grouped into","simulate off-target effects. We include datasets that capture a range of molecular interactions, grouped into",two categories: protein–ligand binding and drug–drug interactions.,two categories: protein–ligand binding and drug–drug interactions.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
two categories: protein–ligand binding and drug–drug interactions.,two categories: protein–ligand binding and drug–drug interactions.,6.4.1 Protein-Ligand Binding Databases,Protein-Ligand Binding Databases,5.74,29.89,0,0,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,9,9,0
6.4.1 Protein-Ligand Binding Databases,Protein-Ligand Binding Databases,"Protein–ligand binding describes the specific interactions between proteins often therapeutic targets or receptors and small-molecule ligands including drugs. These interactions drive most biochemical modulation and are critical for drug discovery, off-target prediction, and mechanistic studies. Below, we summarize","tion and are critical for drug discovery, off-target prediction, and mechanistic studies. Below, we summarize",11.07,-29.89,0,0,1,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,9,9,0
"Protein–ligand binding describes the specific interactions between proteins often therapeutic targets or receptors and small-molecule ligands including drugs. These interactions drive most biochemical modulation and are critical for drug discovery, off-target prediction, and mechanistic studies. Below, we summarize","tion and are critical for drug discovery, off-target prediction, and mechanistic studies. Below, we summarize",several widely used public datasets.,several widely used public datasets.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
several widely used public datasets.,several widely used public datasets.,"ChEMBL 122 is a manually curated database focusing on bioactive molecules with drug-like properties. To assess the binding affinity of small-molecule ligands to their targets, ChEMBL primarily uses","erties. To assess the binding affinity of small-molecule ligands to their targets, ChEMBL primarily uses",4.92,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,9,9,0
"ChEMBL 122 is a manually curated database focusing on bioactive molecules with drug-like properties. To assess the binding affinity of small-molecule ligands to their targets, ChEMBL primarily uses","erties. To assess the binding affinity of small-molecule ligands to their targets, ChEMBL primarily uses","experimental bioactivity data extracted from scientific literature. To facilitate comparison and analysis, data","experimental bioactivity data extracted from scientific literature. To facilitate comparison and analysis, data",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"experimental bioactivity data extracted from scientific literature. To facilitate comparison and analysis, data","experimental bioactivity data extracted from scientific literature. To facilitate comparison and analysis, data","from different sources undergoes a standardization process so that measurement type, value, and units are","from different sources undergoes a standardization process so that measurement type, value, and units are",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"from different sources undergoes a standardization process so that measurement type, value, and units are","from different sources undergoes a standardization process so that measurement type, value, and units are","comparable. In addition to binding affinity measurements, ChEMBL also contains rich information about","comparable. In addition to binding affinity measurements, ChEMBL also contains rich information about",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"comparable. In addition to binding affinity measurements, ChEMBL also contains rich information about","comparable. In addition to binding affinity measurements, ChEMBL also contains rich information about","compounds, targets, experimental assays, and original sources. The current release of ChEMBL release 35","compounds, targets, experimental assays, and original sources. The current release of ChEMBL (release 35)",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"compounds, targets, experimental assays, and original sources. The current release of ChEMBL release 35","compounds, targets, experimental assays, and original sources. The current release of ChEMBL (release 35)",includes approximately 2.5 million distinct compounds and 21.1 million bioactivity measurements derived,includes approximately 2.5 million distinct compounds and 21.1 million bioactivity measurements derived,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
includes approximately 2.5 million distinct compounds and 21.1 million bioactivity measurements derived,includes approximately 2.5 million distinct compounds and 21.1 million bioactivity measurements derived,"from 1.7 million biological assays across 16,000 biomolecular targets. ChEMBL supports a wide range","from 1.7 million biological assays across 16,000 biomolecular targets. ChEMBL supports a wide range",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"from 1.7 million biological assays across 16,000 biomolecular targets. ChEMBL supports a wide range","from 1.7 million biological assays across 16,000 biomolecular targets. ChEMBL supports a wide range","of applications, including structure–activity relationship analysis, off-target prediction, and drug repurposing. Its datasets are available via web interfaces, APIs, and bulk downloads under open Creative Commons","ing. Its datasets are available via web interfaces, APIs, and bulk downloads under open Creative Commons",4.92,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
"of applications, including structure–activity relationship analysis, off-target prediction, and drug repurposing. Its datasets are available via web interfaces, APIs, and bulk downloads under open Creative Commons","ing. Its datasets are available via web interfaces, APIs, and bulk downloads under open Creative Commons",licenses.,licenses.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,9,9,1
PDBbind Dataset 126 was created to collect experimentally measured binding data from literature for,PDBbind Dataset [126] was created to collect experimentally measured binding data from literature for,the biomolecular complexes with high-resolution 3D structures in the Protein Data Bank PDB. It provides,the biomolecular complexes with high-resolution 3D structures in the Protein Data Bank (PDB). It provides,1.02,-14.94,0,0,1,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
the biomolecular complexes with high-resolution 3D structures in the Protein Data Bank PDB. It provides,the biomolecular complexes with high-resolution 3D structures in the Protein Data Bank (PDB). It provides,"an essential linkage between the energetic and structural information of those complexes, which is helpful for","an essential linkage between the energetic and structural information of those complexes, which is helpful for",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"an essential linkage between the energetic and structural information of those complexes, which is helpful for","an essential linkage between the energetic and structural information of those complexes, which is helpful for","various computational and statistical studies on docking validation, scoring-function development, affinity","various computational and statistical studies on docking validation, scoring-function development, affinity",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"various computational and statistical studies on docking validation, scoring-function development, affinity","various computational and statistical studies on docking validation, scoring-function development, affinity","prediction, molecular recognition, and drug discovery. The most recent version 2024 was released on a","prediction, molecular recognition, and drug discovery. The most recent version (2024) was released on a",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"prediction, molecular recognition, and drug discovery. The most recent version 2024 was released on a","prediction, molecular recognition, and drug discovery. The most recent version (2024) was released on a",commercial platform called PDBbind+ with a free demo version. It currently contains experimental binding,commercial platform called PDBbind+ with a free demo version. It currently contains experimental binding,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
commercial platform called PDBbind+ with a free demo version. It currently contains experimental binding,commercial platform called PDBbind+ with a free demo version. It currently contains experimental binding,"affinity data for 27,385 protein-ligand complex, 4,594 protein-protein complex, 1.440 protein-nucleic acid","affinity data for 27,385 protein-ligand complex, 4,594 protein-protein complex, 1.440 protein-nucleic acid",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"affinity data for 27,385 protein-ligand complex, 4,594 protein-protein complex, 1.440 protein-nucleic acid","affinity data for 27,385 protein-ligand complex, 4,594 protein-protein complex, 1.440 protein-nucleic acid",complex and 234 nucleic acid-ligand complex.,complex and 234 nucleic acid-ligand complex.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
complex and 234 nucleic acid-ligand complex.,complex and 234 nucleic acid-ligand complex.,"Metz Dataset 123 focused exclusively on kinase inhibition activities. It contains over 150,000 kinase","Metz Dataset [123] focused exclusively on kinase inhibition activities. It contains over 150,000 kinase",0.96,14.94,0,0,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,10,10,0
"Metz Dataset 123 focused exclusively on kinase inhibition activities. It contains over 150,000 kinase","Metz Dataset [123] focused exclusively on kinase inhibition activities. It contains over 150,000 kinase","inhibitory measurements, comprising more than 3,800 compounds tested against 172 different protein kinases. Based on these measurements, the authors constructed a comprehensive kinome interaction network,","nases. Based on these measurements, the authors constructed a comprehensive kinome interaction network,",4.94,-14.94,0,0,1,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"inhibitory measurements, comprising more than 3,800 compounds tested against 172 different protein kinases. Based on these measurements, the authors constructed a comprehensive kinome interaction network,","nases. Based on these measurements, the authors constructed a comprehensive kinome interaction network,",enabling systematic analysis of kinase–inhibitor interactions. This dataset is applicable not only to binding,enabling systematic analysis of kinase–inhibitor interactions. This dataset is applicable not only to binding,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
enabling systematic analysis of kinase–inhibitor interactions. This dataset is applicable not only to binding,enabling systematic analysis of kinase–inhibitor interactions. This dataset is applicable not only to binding,affinity prediction but also to the design of multi-kinase inhibitors.,affinity prediction but also to the design of multi-kinase inhibitors.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
affinity prediction but also to the design of multi-kinase inhibitors.,affinity prediction but also to the design of multi-kinase inhibitors.,Davis Dataset 125 was developed by Davis et al. to provide a broad target panel covering over 80%,Davis Dataset [125] was developed by Davis et al. to provide a broad target panel covering over 80%,0.96,14.94,0,0,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,10,10,0
Davis Dataset 125 was developed by Davis et al. to provide a broad target panel covering over 80%,Davis Dataset [125] was developed by Davis et al. to provide a broad target panel covering over 80%,of the human catalytic kinome. It includes selectivity profiles of 72 kinase inhibitors tested against 442,of the human catalytic kinome. It includes selectivity profiles of 72 kinase inhibitors tested against 442,1.02,-14.94,0,0,1,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
of the human catalytic kinome. It includes selectivity profiles of 72 kinase inhibitors tested against 442,of the human catalytic kinome. It includes selectivity profiles of 72 kinase inhibitors tested against 442,"human kinases. With more than 30,000 high-precision measurements obtained from a standardized binding","human kinases. With more than 30,000 high-precision measurements obtained from a standardized binding",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"human kinases. With more than 30,000 high-precision measurements obtained from a standardized binding","human kinases. With more than 30,000 high-precision measurements obtained from a standardized binding","assay, the dataset supports various tasks such as binding affinity prediction, selectivity profiling, off-target","assay, the dataset supports various tasks such as binding affinity prediction, selectivity profiling, off-target",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"assay, the dataset supports various tasks such as binding affinity prediction, selectivity profiling, off-target","assay, the dataset supports various tasks such as binding affinity prediction, selectivity profiling, off-target","prediction, and regression model validation. The uniform experimental design and extensive kinase coverage","prediction, and regression model validation. The uniform experimental design and extensive kinase coverage",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"prediction, and regression model validation. The uniform experimental design and extensive kinase coverage","prediction, and regression model validation. The uniform experimental design and extensive kinase coverage",make the dataset a preferred benchmark for visually screening compound libraries and identifying novel,make the dataset a preferred benchmark for visually screening compound libraries and identifying novel,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
make the dataset a preferred benchmark for visually screening compound libraries and identifying novel,make the dataset a preferred benchmark for visually screening compound libraries and identifying novel,inhibitors.,inhibitors.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
inhibitors.,inhibitors.,Via a systematic evaluation of target selectivity profiles across three different biochemical assays of,Via a systematic evaluation of target selectivity profiles across three different biochemical assays of,1,14.94,0,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,10,10,0
Via a systematic evaluation of target selectivity profiles across three different biochemical assays of,Via a systematic evaluation of target selectivity profiles across three different biochemical assays of,"kinase inhibitors, Tang et al. 124 introduced a model-based approach and a unified affinity metric known","kinase inhibitors, Tang et al. [124] introduced a model-based approach and a unified affinity metric known",1,-14.94,0,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"kinase inhibitors, Tang et al. 124 introduced a model-based approach and a unified affinity metric known","kinase inhibitors, Tang et al. [124] introduced a model-based approach and a unified affinity metric known","as the “KIBA score”, to integrate complementary information captured by different bioactivity types. The","as the “KIBA score”, to integrate complementary information captured by different bioactivity types. The",1,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"as the “KIBA score”, to integrate complementary information captured by different bioactivity types. The","as the “KIBA score”, to integrate complementary information captured by different bioactivity types. The","resulting KIBA Dataset comprises a drug–target bioactivity matrix involving 52,498 chemical compounds","resulting KIBA Dataset comprises a drug–target bioactivity matrix involving 52,498 chemical compounds",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"resulting KIBA Dataset comprises a drug–target bioactivity matrix involving 52,498 chemical compounds","resulting KIBA Dataset comprises a drug–target bioactivity matrix involving 52,498 chemical compounds","and 467 kinase targets, with a total of 246,088 KIBA scores. This statistically harmonized dataset, designed","and 467 kinase targets, with a total of 246,088 KIBA scores. This statistically harmonized dataset, designed",1,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"and 467 kinase targets, with a total of 246,088 KIBA scores. This statistically harmonized dataset, designed","and 467 kinase targets, with a total of 246,088 KIBA scores. This statistically harmonized dataset, designed","to minimize experimental variability, has become a widely used benchmark for training machine learning","to minimize experimental variability, has become a widely used benchmark for training machine learning",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"to minimize experimental variability, has become a widely used benchmark for training machine learning","to minimize experimental variability, has become a widely used benchmark for training machine learning",models in drug–target affinity prediction.,models in drug–target affinity prediction.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
models in drug–target affinity prediction.,models in drug–target affinity prediction.,6.4.2 Drug–Drug Interaction Databases,Drug–Drug Interaction Databases,5.74,29.89,0,0,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,10,10,0
6.4.2 Drug–Drug Interaction Databases,Drug–Drug Interaction Databases,"While comprehensive resources such as DrugBank include DDI information, they often require additional","While comprehensive resources such as DrugBank include DDI information, they often require additional",3.23,-29.89,0,0,1,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,10,10,0
"While comprehensive resources such as DrugBank include DDI information, they often require additional","While comprehensive resources such as DrugBank include DDI information, they often require additional","processing to extract pure interaction data. Furthermore, they may not include all the measurements from","processing to extract pure interaction data. Furthermore, they may not include all the measurements from",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"processing to extract pure interaction data. Furthermore, they may not include all the measurements from","processing to extract pure interaction data. Furthermore, they may not include all the measurements from","high-throughput screening assays, for example, dose responses for different dose combinations of drug","high-throughput screening assays, for example, dose responses for different dose combinations of drug",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"high-throughput screening assays, for example, dose responses for different dose combinations of drug","high-throughput screening assays, for example, dose responses for different dose combinations of drug","pairs. Below, we highlight some widely used datasets for both adverse and synergistic DDI prediction","pairs. Below, we highlight some widely used datasets for both adverse and synergistic DDI prediction",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"pairs. Below, we highlight some widely used datasets for both adverse and synergistic DDI prediction","pairs. Below, we highlight some widely used datasets for both adverse and synergistic DDI prediction","tasks. For adverse or general DDI prediction, commonly used datasets include TWOSIDES 127, Deng’s","tasks. For adverse or general DDI prediction, commonly used datasets include TWOSIDES [127], Deng’s",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"tasks. For adverse or general DDI prediction, commonly used datasets include TWOSIDES 127, Deng’s","tasks. For adverse or general DDI prediction, commonly used datasets include TWOSIDES [127], Deng’s","Dataset 128, and ChChMiner 129.","Dataset [128], and ChChMiner [129].",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,10,10,1
"Dataset 128, and ChChMiner 129.","Dataset [128], and ChChMiner [129].",TwoSIDES 127 is a database of polypharmacy side effects for pairs of drugs. It was constructed by,TwoSIDES [127] is a database of polypharmacy side effects for pairs of drugs. It was constructed by,0.96,14.94,0,0,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,10,10,0
TwoSIDES 127 is a database of polypharmacy side effects for pairs of drugs. It was constructed by,TwoSIDES [127] is a database of polypharmacy side effects for pairs of drugs. It was constructed by,mining the U.S. Food and Drug Administration FDA adverse event reporting systems FAERS 133. The,mining the U.S. Food and Drug Administration (FDA) adverse event reporting systems (FAERS) [133]. The,1.02,-14.94,0,0,1,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
mining the U.S. Food and Drug Administration FDA adverse event reporting systems FAERS 133. The,mining the U.S. Food and Drug Administration (FDA) adverse event reporting systems (FAERS) [133]. The,"dataset consists of 868,221 statistically significant association between 59,220 drug pairs and 1,301 adverse","dataset consists of 868,221 statistically significant association between 59,220 drug pairs and 1,301 adverse",1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"dataset consists of 868,221 statistically significant association between 59,220 drug pairs and 1,301 adverse","dataset consists of 868,221 statistically significant association between 59,220 drug pairs and 1,301 adverse",events. Only associations that cannot be clearly attributed to either drug alone were included. It improves,events. Only associations that cannot be clearly attributed to either drug alone were included. It improves,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
events. Only associations that cannot be clearly attributed to either drug alone were included. It improves,events. Only associations that cannot be clearly attributed to either drug alone were included. It improves,the detection and prediction of adverse effects of drug interactions.,the detection and prediction of adverse effects of drug interactions.,1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
the detection and prediction of adverse effects of drug interactions.,the detection and prediction of adverse effects of drug interactions.,"Deng’s Dataset 128 consists of 74,528 distinct drug–drug interactions among 572 approved drugs","Deng’s Dataset [128] consists of 74,528 distinct drug–drug interactions among 572 approved drugs",0.96,14.94,0,0,0,9.96,9.96,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,10,10,0
"Deng’s Dataset 128 consists of 74,528 distinct drug–drug interactions among 572 approved drugs","Deng’s Dataset [128] consists of 74,528 distinct drug–drug interactions among 572 approved drugs",extracted from DrugBank entries by appling NLP algorithms. Each interaction is recorded as a four-element,extracted from DrugBank entries by appling NLP algorithms. Each interaction is recorded as a four-element,1.02,-14.94,0,0,1,9.96,9.96,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
extracted from DrugBank entries by appling NLP algorithms. Each interaction is recorded as a four-element,extracted from DrugBank entries by appling NLP algorithms. Each interaction is recorded as a four-element,"tuple:  drug A, drug B, mechanism, action , where the ‘mechanism’ means the effect of drugs in terms","tuple: (drug A, drug B, mechanism, action), where the ‘mechanism’ means the effect of drugs in terms",1,0,1,1,0,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"tuple:  drug A, drug B, mechanism, action , where the ‘mechanism’ means the effect of drugs in terms","tuple: (drug A, drug B, mechanism, action), where the ‘mechanism’ means the effect of drugs in terms","of the metabolism, the serum concentration, the therapeutic efficacy and so on. The ‘action’ represents","of the metabolism, the serum concentration, the therapeutic efficacy and so on. The ‘action’ represents",1,0,1,0,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
"of the metabolism, the serum concentration, the therapeutic efficacy and so on. The ‘action’ represents","of the metabolism, the serum concentration, the therapeutic efficacy and so on. The ‘action’ represents",increase or decrease. The categorization of interactions into different types of mechanism of actions is,increase or decrease. The categorization of interactions into different types of mechanism of actions is,1,0,1,1,1,9.96,9.96,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,10,10,1
